Document:

Exhibit
10.1

 

Portions of this Exhibit have been omitted
and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such portions are marked
by [***].

 

Confidential

 

SECOND AMENDED AND RESTATED MASTER
SERVICES AGREEMENT

 

PREAMBLE

 

This
confidential SECOND AMENDED AND RESTATED MASTER SERVICES AGREEMENT (the “Master
Agreement”)  is dated as of July 26 2012 and made effective as of May 15, 2012
(“Effective Date”) between GLAXOSMITHKLINE BIOLOGICALS S.A. with offices situated at 89 rue de l’Institut,
1330 Rixensart, Belgium, duly registered under the Belgian Company Register with the number RPM Nivelles BE 440.872.918 (“GSK”),
and RESPONSE GENETICS INC., a company incorporated in the State of Delaware, whose principal place of business is situated at
1640 Marengo Street, Suite 600, Los Angeles, CA 90033 (“RGI”). 

 

WHEREAS, the
Parties entered into that certain Master Agreement dated December 1, 2006 (as amended on November 29, 2007 and amended and restated
in its entirety on August 10, 2009 (the “Original Agreement Effective Date”) (as amended with that certain
First Amendment to the Original Agreement, dated as of December 15, 2011 and as further amended with that certain Second Amendment
to the Original Agreement, dated February 22, 2012, the “Original Agreement”); and

 

WHEREAS, the
Parties wish to amend and restate in its entirety the Original Agreement as is set forth herein effective as of the Effective
Date.

 

NOW THEREFORE,
in consideration of the covenants and obligations expressed herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, and intending to be legally bound the Parties agree as follows:

 

DEFINITIONS

 

In this Master Agreement, the following
initially capitalized terms shall have the following meanings:

 

    	 

    	 	

    
 

 

“Affiliate” with respect
to a person shall mean any other person that directly, or indirectly through one or more intermediaries, controls, is controlled
by or is under common control with such person; for the purposes of this definition only, “control” and, with correlative
meanings, the terms “controlled by” and “under common control with”, shall mean (a) the possession, directly
or indirectly, of the power to direct the management or policies of a person, whether through the ownership of voting securities,
by contract or otherwise, or (b) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities
or other ownership interest of a person.

 

“Analytical Plan” shall
mean a formal authorized document that describes all aspects of the Services to be performed by RGI at RGI’s Facility in
the framework of a Study.

 

“Applicable Laws” shall
mean all applicable provisions of all statutes, laws, rules, regulations, administrative codes, ordinances, decrees, orders, decisions,
injunctions, awards judgments, permits and licenses of or from governmental authorities, including, without limitation, those
relating to or governing the use or regulation of the subject item.

 

“Assay-Related Data”
shall mean any and all data and information that are related to an assay or a GSK Assay that is performed by RGI within the framework
of the Services to be rendered under this Master Agreement as further described in a Task Order. This includes, without limitation,
all Raw Data, quality control charts, technician certification documents, assay Procedures, qualification or validation of assay
protocol and report, documentation on bridging of assays, QC panel protocol and report.

 

“Change Order” shall
mean a specific form of amendment to a Task Order, to be used when the Parties mutually agree to modify the scope of the Services
or the assumptions on which a Task Order is based. A Change Order form is attached to this Master Agreement as Exhibit B.

 

“Critical” shall mean
anything which has direct impact on the GSK Results or on Samples from a Study.

 

“Effective Date”
shall have the meaning set forth in the Preamble.

 

    	- 2 -

    	 

    
 

 

“GSK Equipment”
shall mean any equipment that will be provided to RGI by or on behalf of GSK or its Affiliate, or (ii) that will be purchased
by RGI on behalf of and paid by GSK or its Affiliates during the term of this Master Agreement or any Task Order to perform the
Services hereunder and that shall be listed, if applicable, in Schedule E attached to the relevant Task Order.

 

“Expiration Date”
of this Master Agreement shall mean December 31, 2014 subject to the provision set forth in Section 12 of this Master Agreement.

 

“Facility” shall mean
premises of RGI including RGI’s subcontractor’s premises, where the Services shall be carried out.

 

“GSK Assay” shall mean
any analytical method, diagnostic, primer, probe, or reagent, developed, qualified or validated by or on behalf of GSK which is
transferred to RGI to carry out the Services under the Master Agreement as further described in a Task Order.

 

“GSK Confidential Information”
shall mean all information (including, without limitation, Study Protocols, case report forms, clinical data, other data, reports,
specifications, computer programs or models and related documentation, know-how, trade secrets, including, without limitation,
any technologies and know-how pertaining to GSK Assay(s) or business or research plans) of GSK or GSK’s Affiliates that
are: (1) provided to RGI or RGI’s Affiliates in connection with this Master Agreement or a Task Order, or in connection
with a request for proposals, proposals, or otherwise related to a project which potentially could be the subject of a Task Order,
whether or not a Task Order is ever executed; or (2) created or developed by RGI, RGI’s Affiliates or a Third Party associated
with RGI (including, without limitation, RGI’s employees, agents, or subcontractors), or by Study Investigators and staff,
in connection with this Master Agreement or a Task Order. This Master Agreement and the terms and conditions herein shall be considered
to be GSK Confidential Information.

 

“GSK Results” shall
mean all discoveries, developments, inventions (whether patentable or not), improvements, works of authorship, formulas, processes,
materials components, formulations, methods of use or delivery, clinical data, Assay Related Data, materials, other data, reports,
specifications, computer programs or models and related documentation, know-how or trade secrets, which are conceived or generated
or first reduced to practice by GSK, its Affiliates or RGI, its Affiliates or a Third Party associated with RGI or RGI’s
Affiliates (including, without limitation, RGI’s and RGI’s Affiliates’ employees, agents, or subcontractors),
or by Study Investigators and staff: (1) in connection with performance of Services under this Master Agreement and in a Task
Order, or (2) which reflect or contain GSK Confidential Information, or (3) which relate to Samples under study, including any
results arising from the performance of Samples Management Services, or (4) to Materials or GSK Assay(s) provided by GSK under
this Master Agreement or any Task Order. 

 

    	- 3 -

    	 

    
 

 

“GSK Manager” shall
be designated by GSK in writing to RGI within five (5) business days of the date hereof, or such other representative which GSK
may subsequently designate in writing, who will liaise on the overall requirements for the Services to be performed under this
Master Agreement.

 

“GSK Representative”
shall mean an individual designated by GSK to be responsible for the performance of the Services as set forth in a Task Order.

 

“GxP” shall
mean collectively Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), Good Clinical Practices (GCP) and Good
Clinical Laboratory Practices (GCLP).

 

“Investigator” shall
mean the individual responsible for the conduct of a Study whose role is as defined by ICH GCP.

 

“Key Performance Indicators”
or “KPIs” shall mean the metrics and measures that will allow evaluation of the performance by RGI and its Affiliates
of the Services according to the terms of this Master Agreement and the specifications set forth in the Task Orders(s). The KPIs
shall be specified in Exhibit C of this Master Agreement.

 

“Laboratory Services”
shall mean any clinical testing activities that shall be performed by RGI or its Affiliates within the framework of a Study as
set forth in a Task Order as further described in Section 2.2(b) and (ii) Samples Management Services as further described in
Section 2.2(c).

 

“Materials” shall mean
active and raw materials, reagents, intermediates, processing aids, ingredients or components, documentation and other materials,
including any materials relating to a GSK Assay that will be provided to RGI or its Affiliates by GSK or its Affiliate during
the term of this Master Agreement to perform the Services hereunder and that shall be described in Schedule E attached to the
relevant Task Order.

 

    	- 4 -

    	 

    
 

“Non Assay-Related Data”
shall mean any and all data and information regarding the Services performed by RGI or its Affiliates under this Master Agreement
as further described in a Task Order which are not directly related to an assay, including a GSK Assay. This includes, without
limitation, all records of relevant personnel (e.g. training, CV, job description), transversal Procedures and other transversal
training documents, training records of employees involved in the performance of the Services, documentation on equipment (including
computerized systems) validation and maintenance (IQ/OQ/PQ, qualification, logbook, etc.), reagents, documentation and deviation
reports.

 

“Operational Management Services”
shall mean any activity pertaining to the organization, the set-up and the management of a Study, including but not limited to,
Study project initiation, Study site services, Study project management, Samples Management Services, as further described in
Sections 2.2 (a) and (c) of this Master Agreement.

 

“Party” or “Parties”
shall mean, when used in the singular, either GSK or RGI, as the context requires, and, when used in the plural, shall mean
GSK and RGI.

 

“Person” shall mean
any natural person, corporation, unincorporated organization, partnership, association, joint stock company, joint venture, limited
liability company, trust or government, or any agency or political subdivision of any government, or any other entity.

 

“Procedure” shall mean
any specificities or analytical methods pertaining to the Services to be carried out by RGI or its Affiliates under a Task Order,
including, without limitation, the conditions under which the Services are to be performed, which has been accepted by both RGI
or its Affiliates and GSK or its Affiliates and makes up an integral part of the Task Order.

 

“Raw Data” shall mean
all original records and documentation, or verified copies of these, generated by observations and activities carried out during
the performance of the Services and which have not been subject to processing or any other manipulation. They are necessary for
the reconstruction and evaluation of the reported Study results. For the purposes of this guideline, “source data”
(ICH GCP) and “Raw Data” are the same.

 

 

    	- 5 -

    	 

    

 

“RGI Confidential Information”
shall mean all information (including, without limitation, computer programs or models and related documentation, extraction technology,
assays, procedures, processes, techniques, resourcing, pricing, and billing information, know-how
or trade secrets related to clinical study management, clinical testing, or business or research plans), financial disclosures
or general commercial information of RGI or RGI’s Affiliates that are provided to GSK in connection with this Master Agreement
or a Task Order, or in connection with a request for proposals, proposals, or otherwise related to a project which potentially
could be the subject of a Task Order, whether or not a Task Order is ever executed; provided, however RGI Confidential Information
shall not include any GSK Works, GSK Results or Assay-Related Data.

 

“RGI Results” shall
mean all discoveries, developments, inventions (whether patentable or not), improvements, works of authorship, processes, reports,
specifications, computer programs or models and related documentation, know-how, technology, or trade secrets which are related
to clinical study management, data collection, data management, clinical testing or project management and which are made by RGI
or its Affiliates or subcontractors: (1) other than at the specific request of GSK and at GSK’s cost under a Task Order,
or (2) without reference to or use of GSK Confidential Information or GSK Assay or GSK Results.

 

"RGI Manager" shall be
designated by RGI in writing to GSK within five (5) business days of the date hereofor such other representative which RGI may
subsequently designate in writing, who will liaise on the overall requirements for the Services to be performed under this Master
Agreement.

 

“RGI Monitor” shall
mean an individual designated by RGI to be responsible for the performance of the Services as designated in the Task Order.

 

“Samples Management
Services” shall mean any services relating to the Samples (other than clinical testing) as further described in Section
2.2(c)

 

“Samples” or
“HBS” shall mean any human biological samples (including any derivatives or progeny thereof) that shall be transferred
to RGI or its Affiliates under this Master Agreement or any Task Orders as well as Data related thereto. “Data” in
this definition shall mean information about the human biological samples such as pathology information, and information regarding
the integrity of the biological materials.

    	- 6 -

    	 

    
 

 

“Services” shall mean
any activities that RGI or its Affiliates will perform as requested from time to time by GSK or its Affiliates and as set forth
in a Task Order. This includes, but is not limited to, the Operational Management Services, Laboratory Services as well as any
other services that RGI or its Affiliates will perform under this Master Agreement, as further set forth in a Task Order.

 

“Study”
shall mean a clinical trial or an epidemiology study relating to GSK’s cancer immunotherapies conducted by, or on behalf
of GSK or its Affiliates, or such a study or trial sponsored by a Third Party that receives support from GSK or GSK’s Affiliates,
within the framework of which the Parties agree then RGI or its Affiliates shall perform the Services.

 

“Study Protocol”
shall mean a statement of the rationale, objectives and statistical design and methodology of a Study, including the conditions
under which the Study is to be performed, which has been accepted by both RGI and GSK or their respective Affiliates.

 

“Study Records” shall
mean Assay Related Data, Non Assay Related Data reference materials, as well as any and all information pertaining to the Services
carried out under this Master Agreement and any Task Order(s) that has to be retained as required by Applicable Laws or guidelines
or upon GSK’s written request.

 

“Task Order” shall
mean a written agreement, including any amendments or changes in scope related to such an agreement, between the Parties or Affiliates
which incorporates by reference the terms of this Master Agreement and also contains terms and conditions specifically applicable
to the performance of Services by RGI or its Affiliates with respect to a specific Study or Studies.

 

“Testing Services”
shall mean RGI’s business of conducting molecular-based tumor tissue profiling using a proprietary and patented process
developed by RGI which involves a complex molecular analysis of specific molecular markers that provides valuable tumor specific
gene expression information obtained from a paraffin preserved fresh or frozen tissue sample, which can help the physician choose
the most appropriate therapy for a patient prior to starting treatment or assist a pharmaceutical company in identifying the appropriate
candidate patient population suitable for a therapy in development.

 

    	- 7 -

    	 

    
 

“Third Party” shall
mean any Person other than GSK or RGI (or their respective Affiliates).

 

The definitions of
the terms in this Master Agreement shall apply equally to the singular and plural forms of the terms defined. Whenever the context
may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,”
“includes” and “including” shall be deemed to be followed by the phrase “without
limitation” (regardless of whether it is actually written there (and drawing no implication from the actual inclusion
of such phrase in some instances after such terms but not others)). The word “will” shall be construed to have
the same meaning and effect as the word “shall.” Unless the context requires otherwise: (a) any definition
of or reference to any agreement, instrument or other document in this Master Agreement shall be construed as referring to such
agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions
on such amendments, supplements or modifications set forth in this Master Agreement); (b) any reference in this Master Agreement
to any person or entity shall be construed to include the person’s or entity’s successors and assigns; (c) the words
“herein,” “hereof” and “hereunder” and words of similar import, shall
be construed to refer to this Master Agreement in its entirety and not to any particular provision of this Master Agreement; and
(d) all references in this Master Agreement to Recitals, Articles, Sections or Exhibits shall be construed to refer to the recitals,
articles, sections and exhibits of this Master Agreement.

    	- 8 -

    	 

    

 

ARTICLE I - TASK ORDERS

 

		1.1	            (a)In the event that, from time to time, GSK and
RGI agree that RGI will provide Services with respect to a Study, the Parties shall enter into a Task Order under this Master
Agreement, which shall define the scope and timelines of RGI’s Services and otherwise set out the additional terms and conditions
applicable to RGI’s Services with respect to the Study. Where the Study is sponsored by a Third Party that receives support
from GSK or GSK’s Affiliates and upon the written request of GSK (which request shall include GSK’s authorization
allowing RGI to perform the Services for such Third Party and to use the applicable GSK Confidential Information, Materials, GSK
Results, GSK Equipment or GSK Assay in connection therewith), RGI shall provide the Services directly to such Third Party sponsor
(or its designate) via a contractual arrangement entered into between such Third Party and RGI.

 

(b)The
Parties hereby agree that as of the Effective Date all Statements of Work (as defined in the Original Agreement) then in effect
under the Original Agreement shall automatically be converted into Task Orders under this Master Agreement and all activities
performed pursuant thereto shall be deemed to be Services governed by and subject to the provisions of this Master Agreement.
A complete list of such Statements of Work is attached to this Master Agreement as Exhibit I. For the avoidance of doubt,
the Original Agreement’s terms and conditions shall govern all activities undertaken thereunder up and until the Effective
Date.

 

		1.2	Each Task Order will incorporate
                                                             by reference the terms of this Master Agreement, but each Task Order
                                                             shall be a unique agreement and shall stand alone with respect to
                                                             any other Task Order. A Task Order form is attached as Exhibit
                                                             A to this Master Agreement.

 

		1.3	GSK and RGI intend that their Affiliates
                                                             may also execute Task Orders. Unless the context requires otherwise,
                                                             references to “GSK” or “RGI” in this Master
                                                             Agreement (and the related rights and obligations) as incorporated
                                                             into such a Task Order shall apply to the GSK Affiliate or RGI Affiliate
                                                             that is a Party to the Task Order.

 

 

 

    	- 9 -

    	 

    
 

 

		1.4	Any Services shall be carried out
                                                             by RGI upon the terms
                                                             and conditions of business set forth in this Master Agreement and
                                                             under specific terms and conditions set forth in each Task Order
                                                             (hereinafter collectively referred to as (the “Terms and
                                                             Conditions”). These Terms and Conditions shall override
                                                             and exclude any other terms and conditions set forth (1) in any purchase
                                                             order or other order issued by GSK to require the performance of
                                                             the Services by RGI
                                                             or (2) in any offer or other document issued by RGI
                                                             with respect to the performance of any Services, which terms
                                                             and conditions could conflict in any way with the Terms and Conditions.
                                                             In addition, if any provisions of a Task Order are in direct conflict
                                                             with this Master Agreement so that the provisions of both cannot
                                                             be given effect, the terms of the Task Order shall govern the specific
                                                             issue.

 

 

ARTICLE II – SERVICES

 

		2.1	RGI agrees to perform the Services,
                                                             supplying any deliverables in accordance with the timetable set out
                                                             and turn-around time as specified in the respective Task Order.

 

		2.2	Subject to the specific terms of
                                                             the Task Order, the Services to be performed by RGI shall generally
                                                             consist of:

 

(a)
 Operational Management Services including:

 

i.Project
management services, which are assured by a dedicated project management team appointed by RGI. This project management team ensures
the good conduct of the Study in accordance with the requirements specified in the Task Order and the mutually agreed Analytical
Plan, including the specifications on timelines. Project management also includes answering relevant questions related to the
Services at no charge to GSK or the Investigator. RGI shall also provide sufficient project management resources to communicate
with the Investigator in a language understandable for Study site personnel, including the Investigator;

 

ii.Transportation
system services, which may include maintaining a shipping system, in compliance with all required regulatory bodies, by which
Samples collection supplies can be delivered to the Study sites, Samples can be shipped from the Study sites, and reports can
be delivered to recipients designated by GSK; or

 

 

 

    	- 10 -

    	 

    

 

iii.Samples
tracking services which may include (a) shipment tracking of Samples from pick-up from any location to any delivery location designated
in writing by GSK as set forth in the Task Order or (b) Samples tracking during the handling, analysis and storage of these Samples
by RGI or any Third Party, as set forth in the Task Order.

 

(b)
Laboratory Services such as:

i.Sample
analysis for follow-up of Study subject, including but not limited to, safety testing, screening for enrolment and disease progression
evaluation;

 

ii.Sample
analysis of the humoral or cellular immune response following administration of a vaccine in the framework of a Study, including
but not limited to, immunochemistry, cell mediated immunology, functional immunology and molecular biology typing of exogenous
agents;

 

iii.assay
development, qualification and validation; or

 

iv.Specific
services in the framework of companion diagnostic assay development, including but not limited to sample preparation and bridiging
testing.

 

(c)Samples
Management Services such as the collection, shipment, dispatching, receipt, preparation, tracking, storage, disposal or destruction
of the Samples obtained within the framework of a Study and provided to RGI or its Affiliates pursuant to this Master Agreement
or any Task Order.

 

(d)
In performing Operational Management Services and Laboratory Services, RGI shall also carry out:

 

i.Samples
handling services, which shall include :

 

a.accepting
transfer from GSK or Study sites of Samples with the understanding that the Samples may have hazardous properties;

 

    	- 11 -

    	 

    
 

 

b.handling
the Samples in compliance with all Applicable Laws and regulations; and

 

c.accepting
sole responsibility for the handling, storage and disposal of all waste products generated in the course of the performance of
the Services by RGI in compliance with all Applicable Laws, including laws governing disposal of hazardous substances, and in
accordance with the provisions set forth in Section 4.1 of this Master Agreement;

 

ii.Samples
storage services in accordance with GSK specifications, as described in Section 4.1 of this Master Agreement.

 

iii.Data
services, including providing assay results and other data in accordance with the data format and transmission as per GSK written
specifications set forth in the relevant Task Order.

 

		2.3	RGI agrees to perform Services in
                                                             full compliance with:

 

(a)the
Terms and Conditions of this Master Agreement;

 

(b)the
terms, specifications and timelines established in the Task Order;

 

(c)the
Study Protocol (if applicable), and any amendments to the Study Protocol;

 

(d)RGI’s
standard operating Procedures or GSK standard operating Procedures as set forth in the relevant Task Order. A copy of the Procedures
that have been developed and validated by RGI shall be provided by RGI upon GSK’s request for GSK’s (and its Affiliates’,
designates, agents and subcontractors) use only in connection with their use and exploitation of the GSK Results and GSK Works
and the GSK Gene Expression Values.

 

(e)Any
analytical methods or other specific requirements laid down by GSK for the Services, such as but not limited to, the corrective
actions required by GSK after the audit of RGI’s Facility in accordance with Section 8 of the Master Agreement;

 

 

    	- 12 -

    	 

    
 

 

(f)FDA
regulations for clinical testing activities, being 21 CFR Part 11 (Electronic Records; Electronic Signatures), 21 CFR Part 58
(Good Laboratory Practice for Nonclinical Laboratory Studies regulations), and 21 CFR Part 310, 312, 314 (Good Clinical Practices);

 

(g)To
the extent required, CLIA, Clinical Laboratory Improvement Amendments, as determined by the Centers of Medicare and Medicaid Services
(CMS), regulating clinical testing on humans in the USA;

 

(h)To
the extent required, relevant EU Directives (Directive 2001/20/EC and Directive 2005/28/EC (Good Clinical Practices), Directive
98/79/EC (IVD)), applicable guidance and the Declaration of Helsinki as amended from time to time;

 

(i)ICH
Good Clinical Laboratory Practices guidelines Q2 and E6, or similar guidelines which may apply in the country of performance of
the Services or any local standards which will be followed for regulatory purposes, including without limitation, standards as
required for Study data to be submitted to the regulatory authority of the country in which the Study is conducted;

 

(j)all
Applicable Laws, including applicable health and safety laws and regulations and all Applicable Laws with respect to the handling
and disposal of infectious or hazardous waste;

 

(k)all
applicable medical privacy laws and regulations; and

 

(l)any
requirements specific to certain Services in the country of performance of the Services, or to local standards
which must be followed for regulatory purposes, as specified in the Task Order; and

 

(k)
Should applicable government regulatory requirements be changed during the term of this Master Agreement, RGI shall make reasonable
efforts to satisfy the new requirements. In the event that compliance with such new regulatory requirements necessitates a change
in the Task Order for a Study, RGI shall submit to GSK a revised technical and cost proposal for GSK acceptance prior to making
any changes in the Task Order for such Study and

 

    	- 13 -

    	 

    
 

 

(l)In
the event of a conflict in government regulations, GSK shall, upon request by RGI, designate which regulations it
wishes RGI to follow in its performance of a particular Study provided
that RGI will be lawfully permitted to comply only with the GSK designated regulations.

 

		2.4	RGI shall use its best commercial
                                                             efforts to perform the Services in accordance with the Key Performance
                                                             Indicators set forth in Exhibit C of the Master Agreement.
                                                             GSK reserves the right to discuss, on a case-by-case basis, the actions
                                                             to be undertaken subsequent to a material failure by RGI to comply
                                                             with the agreed Key Performance Indicators in order to (re)assure
                                                             the quality of the Results generated in the performance of the Services.
                                                             In the event, that despite best efforts, the Parties fail to resolve
                                                             such disagreement regarding RGI’s non-compliance with Key Performance
                                                             Indicators, GSK shall have the right to terminate the affected Task
                                                             Order(s) in accordance with the terms set forth in Section 12.5 of
                                                             this Master Agreement. 

 

		2.5	RGI will assign a RGI Monitor as
                                                             a Study Protocol administrator to coordinate and monitor the Services
                                                             rendered as set forth in the Task Order. A designated GSK Representative
                                                             will be responsible to overview the overall performance of the Services.
                                                             Both the RGI Monitor and the GSK Representative shall be identified
                                                             in each Task Order.

 

		2.6	RGI
                                                                                               agrees that timely completion of
                                                                                               each timeline for the performance
                                                                                               of the Services as set forth in
                                                                                               the Task Order is an essential
                                                                                               and critical business requirement,
                                                                                               and that time is of the essence
                                                                                               regarding RGI’s performance
                                                                                               under a Task Order. RGI agrees
                                                                                               that GSK must provide written acceptance
                                                                                               of RGI’s completion of each
                                                                                               timeline for the performance of
                                                                                               the Services within the mutually-accepted
                                                                                               timeframe set forth in each Task
                                                                                               Order before that portion of the
                                                                                               Services may be considered completed
                                                                                               under a Task Order. RGI shall inform
                                                                                               GSK in writing of the completion
                                                                                               of the Services within three (3)
                                                                                               working days of the completion’s
                                                                                               date. RGI shall notify GSK promptly
                                                                                               (but in no event longer than five
                                                                                               (5) working days) upon becoming
                                                                                               aware of any event or circumstance
                                                                                               which will, or which could reasonably
                                                                                               be expected to cause a delay in
                                                                                               the completion of any Service.
                                                                                               To avoid any issues with timelines,
                                                                                               RGI will not begin any activity
                                                                                               set forth in a draft Task Order
                                                                                               until a fully executed Task Order
                                                                                               has been negotiated and executed.

 

    	- 14 -

    	 

    
 

 

		2.7	In the
                                                             event of any actual or reasonably anticipated failure by RGI to complete
                                                             the Services in compliance with the GSK requirements as defined in
                                                             the Master Agreement or in any Task Order (including, without limitation,
                                                             standards for timely performance) (hereinafter collectively referred
                                                             to as the “Standards”) for any reason other than GSK’s
                                                             acts or omissions or an event described in Section 23.3 (Force majeure)
                                                             of this Master Agreement that is not capable of being cured by RGI
                                                             within thirty (30) days of such date of completion of Services, RGI
                                                             shall immediately notify GSK in writing of such actual or reasonably
                                                             anticipated failure and GSK may at its sole discretion:

 

(a)require
RGI to take reasonable corrective actions (including, if necessary, immediately assigning such additional resources as may be
required) so as to complete Services so that Standards are met,
at no additional cost to GSK;

 

(b)
require RGI to re-perform Services so that Standards are met, at no additional cost
to GSK;

 

(c)
perform affected Services itself or retain a Third Party to perform the affected Services, and if in doing so GSK incurs internal
and external costs RGI agrees that GSK may deduct such costs from future payments due to RGI or be reimbursed by RGI for such
costs within sixty (60) days of GSK’s notification related thereto; provided such deduction or reimbursement shall not be
in excess of the payment which would have been due to RGI under the relevant Task Order had RGI completed the affected Services
in compliance with the Standards. 

 

Action
or inaction by GSK as permitted under this Section 2.7 shall not limit any other right that GSK may have under this Master Agreement
or an applicable Task Order, nor limit any right that GSK may have with respect to a breach by RGI of this Master Agreement or
the applicable Task Order.

 

		2.8	Except as GSK is specifically permitted
                                                             by Section 2.7, any necessary modifications to a Task Order, whether
                                                             following a Study Protocol amendment, procedure modification or not,
                                                             shall be made only by a written Change Order executed by both Parties.
                                                             A Change Order form is attached as Exhibit B to this Master
                                                             Agreement. Each Party shall respond promptly to a request for a Change
                                                             Order made by the other Party. As part of a Change Order request
                                                             or response, RGI will propose, in writing, any necessary modifications
                                                             to the milestone dates, target dates and other timelines, fees, or
                                                             costs described in the Task Order.

 

    	- 15 -

    	 

    
 

 

		2.9	RGI shall not subcontract any Services
                                                             to another entity, including to RGI’s Affiliates, without GSK's
                                                             prior written approval. RGI agrees that any approved subcontractor
                                                             will be required to execute a written agreement which extends all
                                                             relevant obligations of RGI under this Master Agreement and the applicable
                                                             Task Order to the subcontractor. RGI shall also remain completely
                                                             responsible for ensuring the satisfactory performance of all subcontracted
                                                             Services by subcontractors selected by RGI and approved by GSK.

 

 

		2.10	RGI shall prepare reports (including
                                                              any status interim reports) and submit the same to GSK within the
                                                              time period mutually agreed upon by the Parties in the Task Order.

 

(a)All
reports shall be transferred confidentially via a secure forum which shall be compatible with GSK’s data transfer requirements.
This secure system can be installed by RGI or provided by GSK to RGI as mutually agreed upon by the Parties in the Task Order.

 

(b)For
the avoidance of doubt, the Parties agree that any secure forum provided by GSK to RGI to transfer reports shall only be used
by RGI to communicate with GSK on the Services described in the Task Order, such as for providing a validation report or reporting
Study results.

 

(c)RGI
shall make its staff reasonably available to GSK to respond to any relevant questions relating to the provided reports, and shall
provide GSK with an updated report including any relevant additional information as may be required by GSK
without additional costs to GSK, unless the additional information requires additional Services not
included in the Task Order. GSK shall notify RGI upon reasonable delay of its satisfaction with such reports and
updated reports.

 

 

    	- 16 -

    	 

    
 

 

(d)In
addition to any specific reporting requirements under a Task Order, RGI agrees that all status interim reports provided by RGI
shall refer to specific milestones and completed tasks pursuant to the specifications set forth in the Task Order, and any actual
or anticipated delays with respect to the timelines provided in the Task Order. To further improve the communication and project
management under a Task Order, upon RGI’s completion of an action, response, or milestone, RGI will specify in its reports
any required response or action from GSK.

 

		2.11	RGI agrees that it will not, without
                                                              the prior written consent of GSK, which consent shall not be unreasonably
                                                              withheld or delayed, change any Procedure, assay methodology, reagent,
                                                              or reference range for the duration of the applicable Study (as
                                                              defined) under the applicable Task Order (a “Change”).
                                                              RGI shall give GSK prior written notice of any such Change at least
                                                              one (1) month before its implementation and shall promptly make
                                                              available to GSK upon GSK’s written request all available
                                                              comparison data without additional charge so that GSK can assess
                                                              the impact of such Change on the Services performed or on the Study.

 

		2.12	RGI shall at its own expense:

 

(a)provide
and maintain RGI Facility of sufficient size and quality, with an appropriate security level and all labour, plant, machinery,
equipment to enable RGI to fulfill all its obligations under this Master Agreement and the Task Order(s), regardless of whether
any of such equipment aforesaid have been acquired from GSK; and

 

(b)maintain
all RGI premises including RGI’s Facility, RGI’s equipment and RGI’s materials in reasonably good working condition
and in compliance with all relevant regulatory requirements and Applicable Laws; and

 

(c)provide
adequate insurance for all such RGI premises including RGI Facility, machinery and equipment as necessary to address the risks
inherent to RGI’s activities under the Master Agreement and any Task Order(s).

 

 

 

    	- 17 -

    	 

    

 

ARTICLE III - RGI STAFF AND RESOURCES

 

		3.1	RGI agrees that only appropriately
                                                             qualified and experienced staff of RGI will perform the Services
                                                             under a Task Order.

 

		3.2	If GSK requests in writing the replacement
                                                             of any RGI staff due to reasonable and documented concerns regarding
                                                             the performance of the Services, RGI will immediately remove that
                                                             person from the performance of the Services or project and assign
                                                             an appropriately qualified and experienced replacement, at no additional
                                                             cost to GSKand the Parties shall in good faith discuss and adjust
                                                             in writing the timeline of any Services or project affected by such
                                                             change of personnel, provided RGI shall take reasonable steps to
                                                             mitigate any negative effects to such timeline.

 

		3.3	RGI may replace RGI staff providing
                                                             Services under this Master Agreement or a specific Task Order; provided
                                                             that:

 

(a)GSK
shall be given prompt written notice (at least three (3) working days, to the extent possible) of the staff RGI proposes to replace,
and information regarding RGI’s proposed replacement staff; and

 

(b)replacement
of the staff shall be at no additional cost to GSK and shall
not adversely affect the timely and quality performance of the Services,

 

(c)if RGI notifies GSK
that such staffing changes have not been anncounced within RGI, GSK shall maintain such information in confidence until it has
been announced within RGI.

 

ARTICLE IV - SAMPLES – MATERIALS
– EQUIPMENT

 

		4.1	Any Samples, Materials or GSK Equipment
                                                            supplied by GSK to RGI for the purpose of carrying out Services under
                                                            a Task Order shall be listed in the Schedule E of the relevant Task
                                                            Order. These Samples, Materials and GSK Equipment will be Delivered
                                                            Duty Paid (DDP). With regard to the Samples:

 

 

    	- 18 -

    	 

    
 

 

(a)RGI
agrees that any Samples provided by GSK shall not be transferred to any Third Party without the prior written consent of GSK or
unless specified otherwise in the relevant Task Order.

 

(b)
RGI shall be responsible for the storage and disposal of the Samples in accordance with RGI’s Procedures and written
instructions provided by GSK in the applicable Task Order and all Applicable Laws.

 

(c)Samples
shall only be used by RGI for the sole purpose of the performance of the Services in accordance with the terms set forth in the
Task Order(s). For the avoidance of doubt, no modifications of Samples or use other than the performance of the Services as provided
in the Task Order will be permitted without GSK’s prior written agreement. The terms set forth in this Section shall survive
termination or expiration of the Master Agreement and any Task Orders. Within one (1) working day after receipt of Samples,
RGI shall record each Sample provided under this Master Agreement and any Task Order in an appropriate tracking system (the “Tracking
Records”). RGI shall maintain the Tracking Records to reflect any changes in tracked information and any Samples’
transfer as well as record complete consumption or disposal of each and every Sample received under this Master Agreement and
any Task Orders. Any Samples and non-used or remaining Samples provided by or on behalf of GSK to RGI in the course of this Master
Agreement or any Task Orders as well as any Samples derivatives, aliquots or pools shall be recorded in the Tracking Records and
shall be stored under appropriate conditions in RGI’s premises that are secure and clean to maintain Samples’ biological
integrity.

 

(d)RGI
shall be responsible for the storage and disposal of the Samples before, during and after the Services, in accordance with RGI’s
Procedures, written instructions provided by GSK, as applicable, as well as with the provisions set forth in Section 6 of this
Master Agreement and in the applicable Task Order. RGI shall provide adequate storage facility for Samples to be maintained under
appropriate conditions as specified in the Schedule A of each Task Order.  RGI
agrees to establish a contingency plan that guarantee the quality of the stored Samples. Sample storage areas must be monitored
where controlled conditions are required to maintain Samples biological integrity.

 

    	- 19 -

    	 

    
 

 

(e)Except
as set forth in Section 23.3 (Force Majeure), upon receipt of any Samples by RGI, RGI shall be solely responsible for the use,
storage and shipment of those Samples and shall compensate GSK for any lost of, or damages to, any such Samples that may occur
when Samples are under the custody of either RGI or any RGI’s subcontractors or agents. Where applicable, the related compensation
shall be calculated according to certain criteria that will be set forth in the relevant Task Order. RGI will handle the Samples
in compliance with all Applicable Laws.

 

(f)RGI
shall be solely responsible for any waste material generated by RGI in connection with the Services, and warrants that all such
waste material will be handled, stored and disposed of by RGI in compliance with all Applicable Laws.

 

(g)RGI
agrees that any Samples provided by GSK under this Master Agreement and any Task Orders:

i.understood
to be experimental in nature and may have hazardous properties;

 

ii.shall
be used in compliance with all Applicable Laws, rules and regulations;

 

iii.shall
not be used in human subjects; and

 

iv.will
not be administered to man or to animals and will not be used for any reason whatsoever to conduct experiments on animals.

 

(h)RGI
will notify GSK in writing of any adverse effects experienced by persons handling Samples. RGI will promptly notify GSK in writing
of any assay results or other information which suggest: (i) a significant risk for humans, (ii) mutagenicity, (iii) teratogenicity
or (iv) carcinogenicity.

 

		4.2.	Materials and Equipment.

 

(a)RGI
shall provide the material and equipment necessary to perform its obligations relating to the Services at the RGI Facilities.
In the event that the Parties agree that RGI should (i) acquire additional equipment, or (ii) modify existing equipment or RGI
Facility to carry out the Services, or (iii) that GSK will loan GSK Equipment to RGI to enable RGI to carry out the Services,
such acquisition or modification or loan shall be discussed and agreed to by the Parties before incurring any expenses related
thereto. In the event GSK transfers GSK Equipment to RGI for the purpose of performing specific Services under a particular
Task Order, any such GSK Equipment provided by GSK shall be listed in the Schedule E of the relevant Task Order. Unless
otherwise stated in a Task Order, any such GSK Equipment transferred by GSK to RGI under this Master Agreement or any Task Order(s)
shall remain at all times, the exclusive property of GSK, provided risk of loss as to such equipment remains with RGI while in
RGI’s possession.

 

    	- 20 -

    	 

    
 

 

(b)RGI
agrees that it will only use in collecting, analyzing or otherwise handling data and performing Services for GSK, reagents, Procedures
and equipment, including but not limited, to computer, hardware or software systems, which have been qualified or validated for
use within the context of relevant GxP compliance, and are maintained in a suitable state of performance and calibration. Any
exceptions to the aforesaid requirements shall be subject to the prior written agreement of GSK. RGI agrees at GSK's request to
provide such evidence of validation as GSK reasonably requires.

 

(c)With
respect to the GSK Equipment or the Materials provided by GSK to RGI under the Master Agreement or any Task Order, RGI hereby
agrees that:

 

i.RGI
staff which will operate the GSK Equipment will make themselves available for training in using the GSK Equipment;

 

ii.only
qualified and duly trained RGI staff shall have the right to operate the GSK Equipment;

 

iii.the
Materials and GSK Equipment will be used only by RGI to carry out the Services and in accordance with written directions provided
by GSK under the Master Agreement or the relevant Task Order;

 

iv.the
Materials and GSK Equipment will be kept in a safe and secure location, and will be used only by RGI staff designated by RGI as
responsible for carrying out the activities on the GSK Equipment;

 

    	- 21 -

    	 

    
 

 

v.RGI
will take suitable precautions and measures to prevent theft, damage or loss to the Materials and GSK Equipment;

 

vi.RGI
shall at its own expense insure the Materials and GSK Equipment through “All Risks” coverage at its full reinstatement
value; and

 

vii.upon
expiration or termination of the Master Agreement or any Task Order under which GSK has transferred Materials or GSK Equipment
to RGI for the performance of the Services, RGI shall return to GSK any unused Materials and shall, as agreed upon by the Parties,
either (i) return to GSK the GSK Equipment and all system related training materials and documentation provided to RGI or (ii)
buy the GSK Equipment or part of it at a price to be agreed to by the Parties at that time, provided however, that the purchase
price shall in no event be lower than the residual value of the purchased GSK Equipment to be based on the fair market value.

 

(d)Unless
otherwise stated in a Task Order, GSK shall be responsible for, and pay the related costs for, the regular maintenance of the
GSK Equipment in accordance with the contracts for maintenance entered into by GSK and its suppliers regarding the said GSK Equipment
(the “Contract(s) for Maintenance”). A copy of the Contract(s) for Maintenance (and any subsequent amendments)
pertaining to the GSK Equipment shall be provided by GSK to RGI upon request of RGI. Notwithstanding the foregoing provision,
RGI shall ensure the day-to-day maintenance of the GSK Equipment according to GSK specifications or the customary standard of
care applicable to the GSK Equipment.

 

(e)To
allow due regular maintenance of the GSK Equipment, RGI shall provide reasonable access to GSK subcontractors/suppliers to RGI
premises, including RGI Facility, upon reasonable notice.

 

(f)Notwithstanding
foregoing Section 4.2(d) of this Master Agreement, it is understood that GSK’s obligations with respect to the maintenance
of the GSK Equipment shall not extend beyond the maintenance obligations set forth in the related Contract(s) for Maintenance.
In particular, GSK shall in no event be responsible for any breakdown or defect of the GSK Equipment arising out of the improper
use, operation or neglect on the part of RGI or its staff.

 

    	- 22 -

    	 

    
 

 

ARTICLE V - INFORMATION TO BE PROVIDED
BY GSK

 

		5.1	GSK shall provide such information
                                                             reasonably necessary to enable RGI to perform the Services. This
                                                             may include any of the following:

(a)Information
to uniquely identify each Sample to be assayed or information pertaining to the Materials provided by GSK to RGI to carry out
the Services;

 

(b)Information
on the content of any reference control Samples supplied by GSK to RGI to carry out the Services;

 

(c)Detailed
analytical methods, or, if these are available in the public domain, a reference to their publication;

 

(d)Stability
storage protocols with respect to the Samples or Materials provided by GSK to RGI to carry out the Services;

 

(e)Specifications
or other quality limits to which Samples to be assayed are expected to comply with, or, if these are available in the public domain,
a reference to their publication; and

 

(f)Listings
of required validation parameters and acceptance criteria for any assay validations to be carried out by RGI. In the event RGI
determines itself the parameters and the criteria to be used to perform the Services, RGI shall seek prior approval from GSK for
any such parameters and criteria selected by RGI to carry out such Services.

 

ARTICLE VI - SAMPLES AND DATA RETENTION

 

		6.1	The Parties agree that upon completion
                                                             of the Services set forth in a Task Order, RGI shall retain any unused
                                                             Samples or remaining Samples as well as any and all Study Records
                                                             as required by any and all Applicable Laws and guidelines for a period
                                                             of at least fifteen (15) years after the last relevant assay run
                                                             within the framework of each related Study (the “Retention
                                                             Period”). During such Retention Period, RGI shall, upon
                                                             the written agreement or request by GSK:

 

    	- 23 -

    	 

    
 

 

		(a)	Either return to GSK (reasonable
                                                                  shipping costs being borne by GSK) :

 

i.unused
or remaining Samples; or

 

ii.original
Assay-Related Data in case the Services have been performed using a GSK Assay; or

 

iii.original
Raw Data and certified copies of other Assay-Related Data, in case the Services have been performed using an assay other than
a GSK Assay; or

 

iv.certified
copies of Non Assay-Related Data in case the Services have been performed using an assay other than a GSK Assay; or

 

v.original
documentation pertaining to the GSK Equipment validation and maintenance as well as reagents provided by GSK: or

 

		(b)	destroy unused or remaining
                                                                  Samples (related costs being borne by RGI).

 

		6.2	In any event, upon expiration of
                                                             the Retention Period, prior to disposing of any such remaining or
                                                             unused Samples or Study Records (including the original Study Records),
                                                             RGI shall notify GSK in advance, and if GSK so requests, shall deliver
                                                             such remaining or unused Samples and Study Records to GSK, at GSK’s
                                                             costs, rather than dispose of them.

 

		6.3	RGI agrees to provide GSK with original
                                                             Study Records, without additional charge. RGI further agrees to ensure
                                                             these Study Records are available, at any time, for inspection by
                                                             Health or Regulatory Authorities such as FDA, WHO, EMA, or by authorized
                                                             GSK personnel upon reasonable notice.

 

ARTICLE VII - QUALITY ASSURANCE

 

		7.1	RGI agrees and shall ensure that
                                                             all results arising from the performance of the Laboratory Services
                                                             have been generated in accordance with the terms of this Master Agreement
                                                             or the specific terms and specifications set forth in the relevant
                                                             Task Order. RGI shall use its best efforts to ensure that those results
                                                             are free from any laboratory errors, using RGI‘s or GSK’s
                                                             Procedures for review and approval of such results.

 

    	- 24 -

    	 

    
 

 

		7.2	RGI shall be responsible for comparing
                                                             any such results with all specifications, quality limits or acceptance
                                                             criteria provided by GSK.

 

		7.3	In the event RGI’s quality
                                                             system does not comply with GCLP guidelines or GSK’s specific
                                                             quality requirements, an action plan will then be defined and agreed
                                                             to by the Parties to remediate potential identified gaps in RGI’s
                                                             quality system (the “Action Plan”). As the case
                                                             may be, such Action Plan shall be attached to this Master Agreement
                                                             as Exhibit G which shall form an integral part of this Master
                                                             Agreement. The Parties acknowledge that quality is critical in performing
                                                             the Services and therefore, the Parties agree that in case RGI fails
                                                             to comply in all respects with the Action Plan within the agreed
                                                             timelines set forth in the Exhibit G, GSK shall have the right
                                                             to terminate the Master Agreement and any and all executed Task Orders
                                                             immediately upon written notice RGI subject to the terms set forth
                                                             in Section 13.2 of this Master Agreement.

 

		7.4	Services performed by RGI shall be
                                                             compliant with the GSK or RGI’s standard operating Procedures,
                                                             as indicated in the relevant Task Order. This shall be analyzed in
                                                             a written document (i.e. Analytical Plan or similar) and provided
                                                             to GSK for approval before Services are started.

 

		7.5	RGI will immediately notify GSK of
                                                             any Critical deviation by sending a completed deviation document,
                                                             which includes at a minimum the root cause analysis justifying and
                                                             explaining the Critical deviation and the suggested action(s) to
                                                             be taken to remedy to this deviation.

 

		7.6	Assay, equipment and computer system
                                                             validation, assay transfer and assay control used by RGI to carry
                                                             out the Services shall comply with GxP and other applicable regulations.
                                                             RGI shall have procedures in place with respect to any Critical equipment
                                                             used to carry out the Services which describes the use, maintenance,
                                                             cleaning, testing, calibration of this Critical equipment and what
                                                             to do in case of failure. All equipment and each analytical method
                                                             used in the analysis of Study Materials must be appropriately documented,
                                                             validated, controlled and approved. Records demonstrating the validity
                                                             and suitability of such equipment and assays within the RGI Facility
                                                             must be retained.

 

 

    	- 25 -

    	 

    
 

 

		7.7	Critical changes to an assay used
                                                             to perform the Services shall be controlled and validated in agreement
                                                             with GSK before its implementation, and shall result in the issue
                                                             of a further version of the assay description. Analytical platforms/assays
                                                             shall not be changed or modified during the course of the performance
                                                             of the Services, without prior consultation and agreement with GSK.
                                                             Such changes must be controlled, documented and appropriately authorized
                                                             and may result in the need for further assay validation.

 

		7.8	For the avoidance of doubt the Parties
                                                             agree that all GSK Assay-Related Data shall be the sole property
                                                             of GSK. RGI further undertakes that all GSK Assay Related Data shall
                                                             be recorded and kept to comply with the foregoing provisions into
                                                             note books or files, retrievable for GSK and not accessible to any
                                                             other person than RGI.

 

ARTICLE VIII - AUDITS AND INSPECTIONS

 

		8.1	GSK or its authorized representatives
                                                             may, in its sole discretion, conduct on-site compliance audits of
                                                             RGI to verify areas of RGI’s premises, including RGI Facility
                                                             or RGI’s equipment, Materials and GSK Equipment or RGI’s
                                                             Procedures and data connected with the Services as well as Study
                                                             Records, or any laboratories or agencies subcontracted by RGI. RGI
                                                             shall be responsible for gaining the agreement of the subcontracted
                                                             sites that GSK shall conduct a compliance audit. RGI shall receive
                                                             reasonable notice of any such audit, and RGI relevant personnel shall
                                                             attend any audit, deemed appropriate by GSK, at no additional cost
                                                             to GSK. For the avoidance of doubt, RGI shall not charge any additional
                                                             costs to GSK with respect to the conduct of any such on-site-compliance
                                                             audit.

 

		8.2	RGI agrees to provide GSK with original
                                                             Study Records, without additional charge except for reasonable copying
                                                             and shipping charges, upon reasonable notice provided such notice
                                                             is received during the Retention Period subject to Section 6.2. RGI
                                                             further agrees to ensure these Study Records are available, at any
                                                             time, for inspection by government or regulatory authorities such
                                                             as FDA, WHO, EMEA, or for audit by authorized GSK personnel upon
                                                             reasonable notice provided that such notice is received during the
                                                             Retention Period subject to Section 6.2.

 

 

    	- 26 -

    	 

    
 

 

		8.3	RGI will permit representatives of
                                                             governmental or regulatory authorities to inspect areas of RGI’s
                                                             premises, including RGI Facility or RGI’s equipment, Materials
                                                             and GSK Equipment or RGI’s Procedures connected with the Services.
                                                             To the extent possible, RGI shall receive reasonable written notice
                                                             of any such inspection, and GSK personnel may attend any inspection
                                                             as it deems appropriate. RGI agrees that RGI’s relevant personnel
                                                             shall attend any such inspection at no additional cost to GSK. For
                                                             the avoidance of doubt, RGI shall not charge any additional costs
                                                             to GSK in connection with any inspection performed by any such governmental
                                                             or regulatory authorities.

 

		8.4	In the event that any governmental
                                                             or regulatory authorities gives notice to RGI of its intention to
                                                             conduct an inspection at a site(s) at which a Service is being performed
                                                             or take any other regulatory action with respect to Services provided
                                                             to GSK, then RGI will, upon receipt of such notice, promptly give
                                                             GSK notice thereof, and GSK shall have the right to be present at
                                                             any such inspection or regulatory action. In the event that such
                                                             an inspection or regulatory action is performed without notice, RGI
                                                             shall notify GSK as soon as practicably possible thereafter. RGI
                                                             will provide GSK with copies of any documentation issued by the governmental/regulatory
                                                             authority and its proposed response thereto, which response will
                                                             be subject to approval by GSK prior to issuance, the approval of
                                                             GSK not to be unreasonably withheld.

 

		8.5	In the event that the audit carried
                                                             out by GSK or its authorized representatives or the inspection conducted
                                                             by governmental or regulatory authorities or their respective nominated
                                                             representatives reveals evidence of poor management, failure to comply
                                                             with the terms of this Master Agreement or of a Task Order, which
                                                             cause Critical alerts or alert findings, provided any such alerts
                                                             or failure or default have not been resolved, or corrective actions
                                                             requested by GSK have not been implemented, by RGI within thirty
                                                             (30) days after GSK’s notification thereof, then GSK shall
                                                             be entitled to terminate the Master Agreement and related Task Order
                                                             for breach by giving notice of such termination to take effect immediately.

 

		8.6	If RGI becomes aware of any material
                                                             issues related to the performance of a Study Investigator, including
                                                             without limitation, (i) any governmental or regulatory authority
                                                             notification to a Study Investigator that it will inspect the Study
                                                             Investigator’s records, facilities, equipment, or Procedures,
                                                             or (ii) any action taken by any governmental or regulatory authorities
                                                             with respect to a Study, RGI shall notify GSK as soon as is practicable
                                                             (to the extent possible, within two (2) business days prior to the
                                                             occurrence of the inspection or action), and will cooperate with
                                                             GSK regarding responsive action.

 

    	- 27 -

    	 

    
 

 

		8.7	During the term of the Master Agreement,
                                                             RGI will promptly notify GSK in writing of:

(i)any
material action taken by any governmental or regulatory authority with respect to RGI, and provide GSK with copies of any reports
issued by such governmental or regulatory authorities; and

 

(ii)any
action taken by any governmental or regulatory authority with respect to RGI involving a GSK Study or any Services, and provide
GSK with copies of any reports issued by such governmental or regulatory authorities.

 

 

ARTICLE IX - REGULATORY

 

		9.1	During the term of this Master Agreement
                                                             and any Task Order and any renewals thereof, RGI shall secure and
                                                             maintain any and all licenses required by Applicable Laws and regulations
                                                             which are or may become applicable to RGI in connection with the
                                                             Services to be performed by RGI under the Master Agreement or any
                                                             Task Order, including without limitation, compliance with all applicable
                                                             licensing requirements, if any, relating to the collection of Samples
                                                             or removal and disposal of applicable chemical, biological or medical
                                                             waste.

 

 

ARTICLE X - CHANGES IN PREMISES,
EQUIPMENT, INFORMATION OR PROCEDURES

 

		10.1	RGI shall not perform Services in
                                                              any other facility or Facility without first receiving the prior
                                                              written approval of GSK with respect to the use of such new facility
                                                              or Facility.

 

		10.1	RGI will notify GSK within five
                                                              (5) working days of any Critical changes occurring in the premises,
                                                              including RGI Facility, equipment, reagents used to carry out the
                                                              Services, RGI or GSK’s Procedures used for the performance
                                                              of the Services, and, where practicable, will seek GSK’s written
                                                              agreement prior to the change being introduced.

 

 

    	- 28 -

    	 

    
 

 

		10.2	GSK will ensure that RGI is informed
                                                              within five (5) working days of any changes to any of the information
                                                              supplied to RGI regarding the Services, as stated in the respective
                                                              Task Order. In the event, RGI incurs additional costs in implementing
                                                              these changes, the additional costs shall be discussed in good faith
                                                              by the Parties and if mutually agreed to by the Parties, shall be
                                                              reimbursed to RGI by GSK.

 

		10.3	Without prejudice to Section 2.1,
                                                              changes to agreed timelines by either RGI or GSK must be notified
                                                              in accordance with Section 2.7 and accepted in advance and revised
                                                              timelines agreed by the Parties, acting in good faith.

 

ARTICLE
XI – COMPENSATION

 

11.1(a)In
consideration for its performance of Services under a Task Order, GSK shall pay RGI in accordance with the terms of the relevant
Task Order, including any milestone and payment schedule set forth in the Task Order, and in accordance, if applicable, with any
discounts, rebates, or other pricing terms as set forth in Exhibit D attached to and incorporated by reference as part
of this Master Agreement and according to the budget set forth in Schedule B attached to the relevant Task Order (hereinafter
referred to as the “Budget”). GSK shall have no obligation to make payments for any portion of the Services
that is not completed pursuant to the terms and conditions of the Master Agreement or in accordance with the specifications set
forth in the relevant Task Order or for Services that are not covered by a Task Order or a written amendment executed by both
Parties, including a Change Order, or any other cost to which GSK has not specifically agreed to in writing in advance, including,
without limitation, any cost incurred by RGI to satisfactorily complete the Services which exceeds the amount GSK has agreed to
pay for the performance of the Services under the Task Order concerned.

 

(b)Any
significant change to the scope of the Services shall result in an adjustment to the related Budget by amendment and shall be
subject to a Change Order. The fixed costs or reimbursable costs payable to RGI as indicated above may increase or decrease, consistent
with the increase or decrease in the scope of Services or the Budget specifications noted in the Task Order or the related Budget.

 

    	- 29 -

    	 

    
 

 

(c)No
changes to the scope of the Services can be implemented by RGI without prior written approval from GSK Representative. It will
be RGI's responsibility to proactively identify additional services outside the original scope of the Services that need to be
performed in furtherance of the implementation of such change. RGI shall submit to the GSK Representative the costs associated
with the performance of such additional activities for initiating Change Order to the relevant Task Order and this prior to implementation.

 

		11.2	GSK’s payment obligation is
                                                              also conditioned upon RGI
                                                              submitting proper invoices. RGI
                                                              shall submit invoices as provided for in the milestones and
                                                              payments schedule and with any information requirements contained
                                                              in the applicable Task Order, within sixty (60) days of completion
                                                              of the relevant portion of the Services or achievement of relevant
                                                              milestone, to the attention of:

 

Accounting
Department

GlaxoSmithKline
Biologicals SA

Rue
de l’Institut, 89

1330
Rixensart

Belgium

 

The following information
must be indicated on each invoice:

 

(a)Invoice
number;

(b)Study
Protocol number, e-track number (as appropriate);

(c)GSK
Affiliate for which Services are provided (as appropriate);

(d)Invoice
date;

(e)Effective
Date of this Master Agreement and the applicable Task Order;

(f)GSK’s
internal Contract Reference Number, i.e. PO number (to be provided by GSK);

(g)Dates
on which Services were provided;

(h)Total
amount of fees for the Services performed during the invoiced period;

(i)Payee
name and address (for Services provided within U.S., name and address must match the W-9 form submitted by RGI); and

(j)Tax
ID/VAT number (for Services provided within U.S., tax ID number must match the W-9 form submitted by RGI).

 

 

    	- 30 -

    	 

    
 

Failure
to provide the required information will delay approval and the invoice may be returned for revisions. All invoices shall become
payable at the end of the month following sixty (60) days from the receipt by GSK.

 

		11.3	Any discrepancy between the amount
                                                              invoiced to GSK and the Services actually performed by RGI during
                                                              the invoiced period will be notified by GSK to RGI. Regularization
                                                              of the incorrect invoice by RGI shall only be made via a credit
                                                              note referring to the initial invoice, and such corrections shall
                                                              not be deemed to be a delay in payment.

 

		11.4	All sums payable by GSK in respect
                                                              of the Services are exclusive of VAT and any other similar duties
                                                              or taxes. Such sums shall however include all handling, packing,
                                                              delivery and customs charges unless agreed otherwise in writing
                                                              in the Task Order.

 

ARTICLE XII
– TERM AND TERMINATION

 

		12.1	This Master Agreement shall take
                                                              effect on the Effective Date and shall continue until the Expiration
                                                              Date unless earlier terminated as provided below. Each Task Order
                                                              shall take effect as of the effective date designated in the Task
                                                              Order. Termination of this Master Agreement or of any Task Order
                                                              shall not affect any other Task Order; each Task Order shall continue
                                                              in full force and effect unless specifically terminated in accordance
                                                              with the terms of this Master Agreement or the terms of that Task
                                                              Order. Termination of this Master Agreement shall not (unless otherwise
                                                              agreed in writing between the Parties) terminate any Task Order
                                                              which shall continue for the term specified in the Task Order (and
                                                              the Parties shall continue to perform their obligations thereunder)
                                                              unless terminated earlier in accordance with this Master Agreement.
                                                              The Master Agreement shall continue to apply in relation to any
                                                              surviving Task Order for the duration of that Task Order, notwithstanding
                                                              its termination.

 

		12.2	GSK
                                                              may terminate this Master Agreement, without cause, upon
                                                              providing ninety
                                                              (90) days written
                                                              notice to RGI. RGI may
                                                              terminate this Master Agreement, without cause, upon providing one
                                                              year’s prior written notice to GSK. 

 

		12.3	Either Party may terminate this
                                                              Master Agreement or any Task Order immediately upon written notice
                                                              if the other Party becomes insolvent, or if proceedings are instituted
                                                              against the other Party for reorganization or other relief under
                                                              any bankruptcy law, or if any substantial part of the other Party’s
                                                              assets come under the jurisdiction of a receiver or trustee in an
                                                              insolvency proceeding authorized by law. All rights and licenses
                                                              granted under or pursuant to this Agreement by RGI to GSK are, and
                                                              shall otherwise be deemed to be, for purposes of Article 365(n)
                                                              of the U.S. Bankruptcy Code, licenses of rights to “intellectual
                                                              property” as defined under Article 101(52) of the U.S. Bankruptcy
                                                              Code. The Parties agree that each Party, as a licensee of such intellectual
                                                              property rights under this Agreement, shall retain and may fully
                                                              exercise all of its rights and elections under the U.S. Bankruptcy
                                                              Code.

 

    	- 31 -

    	 

    
 

 

		12.4	GSK
                                                              may terminate this Master Agreement or any Task Order immediately
                                                              upon written notice to RGI if there is a change in control of RGI
                                                              by the acquisition by any person or entity, directly or indirectly,
                                                              of more than fifty percent (50%) of the total voting capital stock
                                                              of RGI (or such lesser amount by whuch the acquiring party gains
                                                              control over RGI), or by any sale, lease, exchange or other disposition
                                                              by RGI of all or substantially all of its assets.

 

		12.5	GSK may terminate this Master Agreement
                                                              or a Task Order immediately upon written notice to RGI, if RGI fails
                                                              to remedy a material breach of this Master Agreement within sixty
                                                              (60) days after written notice by GSK to RGI of the breach.

 

		12.6	GSK
                                                              may terminate any Task Order, in whole or in part, without cause,
                                                              upon providing written notice to RGI. 

 

		12.7	RGI may terminate this Master Agreement
                                                              or any Task Order immediately upon written notice to GSK, if GSK
                                                              fails to remedy a material breach of this Master Agreement or the
                                                              relevant Task Order within sixty (60) days after written notice
                                                              by RGI to GSK of the breach.

 

 

ARTICLE XIII - EFFECT OF TERMINATION
OR EXPIRATION

 

		13.1	Upon notice of termination of a
                                                              Task Order by or to RGI, RGI shall use commercially reasonable efforts
                                                              to conclude or transfer any uncompleted Service, as directed by
                                                              GSK, as expeditiously as possible. RGI shall not undertake further
                                                              work, incur additional expenses, or enter into further commitments
                                                              with regard to any Services, except as mutually agreed upon in writing
                                                              by the Parties.

 

 

    	- 32 -

    	 

    
 

 

		13.2	Upon the effective date of termination
                                                              of a Task Order, RGI shall invoice GSK for payments due for Services
                                                              already preformed prior to the effective date of such termination
                                                              and, if termination was by GSK without cause under Section 12.6,
                                                              for reimbursement for all expenses incurred in accordance with the
                                                              Task Order prior to such termination date, provided in each instance
                                                              GSK shall not be obligated to remit payment to RGI for any Services
                                                              that is the subject of an RGI breach. This invoice and any payment
                                                              obligation of GSK are subject to Section 11 of this Master Agreement.
                                                              If, upon the effective date of termination, GSK has advanced funds
                                                              which are unearned by RGI, RGI shall repay such funds to GSK within
                                                              sixty (60) days after the effective date of termination.

 

		13.3	Within thirty (30) days or as soon
                                                              as practicably possible thereafter, or such other period of time
                                                              mutually agreed to in writing by the Parties, after the effective
                                                              date of termination of this Master Agreement or a Task Order, RGI
                                                              shall deliver to GSK all materials, data, and information pertaining
                                                              either to the Study or to the Services which are GSK’s property
                                                              as defined in Article IV of this Master Agreement or the relevant
                                                              Task Order. RGI agrees that this obligation is not conditioned upon
                                                              GSK’s prior payment of amounts due or agreement to pay any
                                                              amounts in dispute.

 

		13.4	Compliance with this Section 13
                                                              does not limit or waive either Party’s potential remedies
                                                              for a breach of this Master Agreement or a relevant Task Order.
                                                              Termination of this Master Agreement or a Task Order shall not release
                                                              either Party from any obligation or right which accrued to that
                                                              Party prior to the effective date of termination or which later
                                                              accrues from an act or omission which occurred prior to the effective
                                                              date of termination.

 

		13.5	Upon termination or expiration of
                                                              this Master Agreement or any Task Order, the following provision
                                                              of this Master Agreement shall survive expiration or termination
                                                              for the time period specified in such provisions or if no such time
                                                              period is specified, indefinitely: “Definitions” (for
                                                              interpretation purposes), Articles VI (Samples and Data Retention,
                                                              XIII (Effect of Termination), XIV (Confidentiality), XV (Intellectual
                                                              Property), XIX (Indemnification), XX (Insurance), XXI (Damages)
                                                              and XXIII (Miscellaneous), and Sections 1.1(b), 1.2, 1.4, 2.10(b),
                                                              2.10(c) (for a one year period after
                                                              the delivery date of the applicable report(s), 4.2(a)(last sentence),
                                                              4.2(c) through 4.2(f), 8.2, 8.7 (only with regard to actions relating
                                                              to GSK Studies or Services), 11.2 and 11.4 (for any outstanding
                                                              payments), 12.1, and 16.6.

 

    	- 33 -

    	 

    
 

 

		13.6	In the event of termination of this
                                                              Agreement by GSK pursuant to Sections 12.3 or 12.4 or 12.5, or by
                                                              RGI pursuant to Section 12.2, GSK shall receive the following items
                                                              (after submitting a request in writing within thirty (30) days after
                                                              the effective date of such termination and at no cost to GSK), solely
                                                              to the extent reasonably necessary for GSK to continue (or have
                                                              continued by its Affiliates or a Third Party the development, commercialization,
                                                              manufacture and supply of any diagnostic test developed as part
                                                              of the Services, and to be able to perform any services (including
                                                              laboratory testing services) that were conducted as part of the
                                                              Services:

(a)
full access and transfer of a copy in electronic form of the data, information, and materials owned or controlled by RGI regarding
the development, commercialization, manufacturing and supply of the Services to GSK (with RGI using its commercially reasonable
efforts to provide such data, information and materials to GSK by thirty (30) days after the receipt of such notice); and

 

(b)
To the extent permitted by law, the transfer of all Regulatory Approvals (or applications therefore) held by RGI its Affiliates
or permitted sublicensees related specifically to the Services, if any, (with RGI using its commercially reasonable efforts to
undertake such actions within thirty (30) days after the receipt of such notice of); and

 

(c)a
non-exclusive, royalty-free worldwide license, with the right to sublicense (to the extent RGI has the right to sublicense), RGI’s
rights in its intellectual property and the RGI Confidential Information to the extent such intellectual property has been used
for, or is necessary for GSK to continue (or have continued by its Affiliates or a Third Party), the development, commercialization,
manufacture or supply of the Services .

 

(d)
RGI’s obligations under this Agreement to manufacture, supply and commercialize the Services (on commercially reasonable
and standard terms to be negotiated and agreed to by both Parties in writing) shall survive termination of this Agreement until
the date on which GSK (or its Affiliate or a third Party acting on GSK’s behalf) is able to perform the Services in a manner
substantially equivalent to the Services provided by RGI in all material respects provided that GSK shall pay RGI for such continued
Services pursuant to the agreed fees.

 

 

    	- 34 -

    	 

    
 

 

(e)Notwithstanding
anything to the contrary set forth in this Master Agreement, with respect to any license or rights granted to GSK to RGI intellectual
property or RGI Confidential Information pursuant to Sections 13.6(a), 13.6(c), 15.6 or 16.6, GSK shall make reasonable best efforts
to ensure that the use of such RGI intellectual property rights or RGI Confidential Information by any GSK Affiliate or any Third
Party shall be limited to the scope of the license or other rights granted to GSK hereunder and such RGI intellectual property
rights or RGI Confidential Information is only used as necessary for GSK to continue the Services or exploit the Services (including
obtaining appropriate written covenants to such effect from any Third Party sublicensees).

 

ARTICLE XIV - CONFIDENTIALITY

 

		14.1	As of and
                                                              after the Effective Date, all Confidential Information disclosed,
                                                              revealed or otherwise made available by one Party (“Disclosing
                                                              Party”) to the other Party (“Receiving Party”)
                                                              under, or as a result of, this Master Agreement is furnished to
                                                              the Receiving Party solely to permit the Receiving Party to exercise
                                                              its rights, and perform its obligations, under this Master Agreement.
                                                              The Receiving Party shall not use any of the Disclosing Party’s
                                                              Confidential Information for any other purpose, and shall not disclose,
                                                              reveal or otherwise make any of the Disclosing Party’s Confidential
                                                              Information available to any other Person without the prior written
                                                              authorization of the Disclosing Party.

 

		14.2	In furtherance
                                                              of the Receiving Party’s obligations under Section 14.1 hereof,
                                                              the Receiving Party shall take reasonable steps, and shall implement
                                                              reasonable safeguards, to prevent the unauthorized use or disclosure
                                                              of any of the Disclosing Party’s Confidential Information.
                                                              Without limiting the generality of this Section 14.2, the Receiving
                                                              Party shall disclose any of the Disclosing Party’s Confidential
                                                              Information only to those of its officers, employees, licensees,
                                                              sublicensees, consultants, attorneys and financial investors that
                                                              have a need to know the Disclosing Party’s Confidential Information,
                                                              in order for the Receiving Party to exercise its rights and perform
                                                              its obligations under this Agreement, and only if such officers,
                                                              employees, licensees, sublicensees, consultants, attorneys and financial
                                                              investors have executed appropriate non-disclosure agreements containing
                                                              substantially similar terms regarding confidentiality as those set
                                                              out in this Agreement or are otherwise bound by obligations of confidentiality
                                                              effectively prohibiting the unauthorized use or disclosure of the
                                                              Disclosing Party’s Confidential Information. The Receiving
                                                              Party shall promptly furnish the Disclosing Party with written notice
                                                              of any known unauthorized use or disclosure of any of the Disclosing
                                                              Party’s Confidential Information by any officer, employee,
                                                              licensee, sublicensees, consultants, attorneys or financial advisors
                                                              of the Receiving Party, and shall take all actions that the Disclosing
                                                              Party reasonably requests in order to prevent any further unauthorized
                                                              use or disclosure of the Disclosing Party’s Confidential Information.

 

    	- 35 -

    	 

    
 

 

		14.3	The Receiving Party’s obligations
                                                              under Sections 14.1 and 14.2 hereof shall not apply to the extent
                                                              that the Receiving Party can prove by written evidence that any
                                                              of the Disclosing Party’s Confidential Information:

 

(a)passed
into the public domain, or becomes generally available to the public through no breach of this Master Agreement or the Original
Agreement by the Receiving Party;

 

(b)was
known to the Receiving Party prior to disclosure hereunder by the Disclosing Party;

 

(c)is
disclosed, revealed or otherwise made available to the Receiving Party by a Third Party that, to the Receiving Party’s knowledge,
is under no obligation relating to the subject item of non-disclosure and/or non-use to the Disclosing Party; or

 

The Receiving Party may disclose
Confidential Information as is required to be disclosed under Applicable Law, or in connection with any application by the Receiving
Party for any Regulatory Approvals; provided, however, that, subject to Section 14.6 below, the Receiving Party shall furnish
the Disclosing Party with as much prior written notice of such disclosure requirement as reasonably practicable, so as to permit
the Disclosing Party, in its sole discretion, and at its sole expense, to take appropriate action, including seeking a protective
order, in order to prevent the Disclosing Party’s Confidential Information from passing into the public domain or becoming
generally available to the public.

 

		14.4	Subject to Sections 6.1 and 13.6,
                                                              upon expiration or termination of this Master Agreement for any
                                                              reason whatsoever, the Receiving Party shall cease all use of and
                                                              return to the Disclosing Party (or destroy, if the Disclosing Party
                                                              specifies in writing) all copies of all documents and other materials
                                                              that contain or embody any of the Disclosing Party’s Confidential
                                                              Information (and irrevocably delete all electronic copies of such
                                                              documents and materials), except to the extent that the Receiving
                                                              Party is required by Applicable Law to retain such documents and
                                                              materials, or if the entire document or material does not contain
                                                              the Disclosing Party’s Confidential Information, then the
                                                              document or material shall be redacted to remove entirely the Disclosing
                                                              Party’s Confidential Information. Within thirty (30) days
                                                              after the date of expiration or termination of this Agreement, the
                                                              Receiving Party shall furnish the Disclosing Party with a certificate,
                                                              duly executed by an officer of the Receiving Party, confirming that
                                                              the Receiving Party has complied with its obligations under this
                                                              Section 14.4.

 

    	- 36 -

    	 

    
 

 

		14.5	All of the Receiving Party’s
                                                              obligations under Sections 14.1 and 14.2 hereof, with respect to
                                                              the protection of the Disclosing Party’s Confidential Information,
                                                              shall for a period of ten (10) years survive the expiration or termination
                                                              of this Master Agreement for any reason whatsoever.

 

		14.6	No public announcement concerning
                                                              the existence of, terms, or subject matter of this Agreement shall
                                                              be made, either directly or indirectly, by either Party, without
                                                              first obtaining the prior written approval of the other Party and
                                                              agreement upon the nature and text of such public announcement which
                                                              such agreement and approval shall not be unreasonably withheld.
                                                              Notwithstanding the foregoing, if, in the opinion of legal counsel
                                                              for the Party desiring to make such public announcement, such disclosure
                                                              is required under Applicable Law, the Party required to make such
                                                              public announcement shall inform the other Party of the proposed
                                                              announcement or disclosure in reasonably sufficient time prior to
                                                              public release, which shall be not less than ten (10) business days
                                                              (or such shorter period as may be required under Applicable Law)
                                                              prior to release of such proposed public announcement, and shall
                                                              provide the other Party with a written copy thereof in order to
                                                              allow such other Party to comment upon such public announcement.
                                                              The Receiving Party shall reasonably cooperate with Disclosing Party
                                                              (at the Disclosing Party’s expense) with respect to all disclosures
                                                              regarding this Master Agreement required under Applicable Law, including
                                                              requests for confidential treatment of proprietary information of
                                                              the Disclosing Party included in any such disclosure. For the avoidance
                                                              of doubt, RGI hereby agrees that (after consultation with its legal
                                                              advisors confirming that no such disclosure is required) it shall
                                                              not issue any press release or other public disclosure of this Master
                                                              Agreement without GSK’s prior consent provided that GSK hereby
                                                              acknowledges RGI may be required to make certain disclosures pursuant
                                                              to the Securities Exchange Act of 1934, as amended from time to
                                                              time, and that the content of such disclosures is reasonably agreed
                                                              by the Parties in advance thereof.

 

 

    	- 37 -

    	 

    
 

 

		14.7	Applicable Law. Nothing in
                                                              this Agreement shall be construed as preventing or in any way inhibiting
                                                              either Party from complying with Applicable Law governing activities
                                                              and obligations undertaken pursuant to this Master Agreement, in
                                                              any manner which it reasonably deems appropriate, including, for
                                                              example, by disclosing to Regulatory Authorities confidential or
                                                              other information received from the other Party, subject to Sections
                                                              14.3 and 14.6.

 

		14.8	Non-Use of Names. Neither
                                                              Party (or its Affiliates) shall use, either directly or indirectly,
                                                              the logo, name, housemarks or trademarks of the other Party (or
                                                              its Affiliates), or any of their officers, employees or board members
                                                              in any publicity, marketing advertising or other documents (or other
                                                              disclosures) without the prior written consent of the other Party
                                                              (in its sole discretion). Each Party will use commercially reasonable
                                                              efforts to review and approve any proposed disclosure within ten
                                                              (10) business days of its receipt from the other Party of a copy
                                                              or transcript of the proposed disclosure. If a Party approves the
                                                              other Party’s usage of its names, trademarks, etc. in accordance
                                                              with this Section 14.8, the other Party shall comply with any usage
                                                              guidelines or requirements imposed by the approving Party.

 

		14.9	Publication. Publication
                                                              in a journal, paper, magazine or any other such similar disclosure
                                                              by RGI describing activities undertaken under this Master Agreement
                                                              or mentioning the name of GSK in relation to this Agreement will
                                                              not take place without the prior written agreement of GSK.
                                                               GSK shall have the sole
                                                              right to publish any results arising from the Services. RGI will
                                                              be acknowledged in all such publications or other public disclosures
                                                              by co-authorship or acknowledgment, whichever is appropriate.

 

ARTICLE XV - INTELLECTUAL PROPERTY

 

		15.1	RGI will disclose promptly to GSK
                                                              in writing any GSK Results. Subject to Section 13.6(e) hereof, RGI
                                                              agrees that GSK Results shall be the sole property of GSK. Without
                                                              limiting the foregoing, and without additional consideration, RGI
                                                              hereby also assigns to GSK all rights, title, and interest RGI may
                                                              have in any GSK Results upon the future creation of such GSK Results.
                                                              RGI agrees to obtain written agreements with RGI employees, agents,
                                                              and subcontractors which assign, without additional consideration,
                                                              all rights, title and interests in GSK Results to GSK or to RGI
                                                              by which RGI can then assign to GSK.

 

    	- 38 -

    	 

    
 

 

		15.2	“GSK Works” shall
                                                              mean all original works of authorship prepared by or for or on behalf
                                                              of GSK in connection with the performance of this Master Agreement
                                                              or any Task Order. All GSK Works shall be “works made for
                                                              hire,” and GSK will own all GSK Works and all copyrights in
                                                              GSK Works. For any GSK Works that, under the copyright laws of the
                                                              United States, may not be considered “works made for hire,”
                                                              RGI agrees to assign to GSK all rights, title, and interest in such
                                                              GSK Works, without payment of any additional compensation to RGI.
                                                              At GSK’s request and expense, RGI shall also reasonably assist
                                                              GSK in obtaining or perfecting GSK’s rights, title, and interest
                                                              in such GSK Works.

 

		15.3	If GSK requests, RGI will execute
                                                              and will cause its employees, agents, or subcontractors to execute
                                                              any instruments or testify as GSK deems necessary for GSK to obtain
                                                              patents or otherwise to protect GSK's interest in a GSK Result.
                                                              GSK will reasonably compensate RGI for the time devoted to such
                                                              activities and will reimburse RGI for
                                                              reasonable and necessary expenses incurred.

 

		15.4	GSK acknowledges RGI’s ownership
                                                              of, (i) the Testing Services, including RGI’s proprietary
                                                              process for extracting nucleic acid and analyzing the samples and
                                                              producing the gene expression values, and all of the materials which
                                                              comprise same, and any accompanying patent information owned by
                                                              RGI, (ii) all intellectual property associated therewith (the “RGI
                                                              Intellectual Property”), and (iii) any algorithms or scales
                                                              created and used by RGI in producing or developing the gene expression
                                                              values (“algorithms”). If GSK directly challenges
                                                              the validity of any claim within an issued patent within the RGI
                                                              Intellectual Property licensed under section 15.6 by filing in any
                                                              country a lawsuit, interference action or the like, then the license
                                                              in that country to the patent under section 15.6 of this Agreement
                                                              shall terminate. With respect to RGI Intellectual Property expressly
                                                              identified herein, if GSK learns of an infringement, unauthorized
                                                              use, misappropriation or threatened infringement by a Third Party
                                                              of such RGI Intellectual Property, GSK shall promptly notify RGI.
                                                              It is understood that neither GSK nor any Affiliate shall acquire
                                                              or claim title to the Testing Services, algorithms, research and
                                                              development, or the RGI Intellectual Property by virtue of this
                                                              Master Agreement, subject to the provisions of Section 13.6 and
                                                              16.6. However, any improvements or modifications thereto which are
                                                              developed during the course of RGI’s performance of the Services
                                                              under the Master Agreement, will be jointly owned by the Parties
                                                              and GSK may, at its discretion and expense, seek patent protection
                                                              for such jointly owned inventions. In case GSK does not wish to
                                                              seek such patent protection, it shall inform RGI thereof and RGI
                                                              may seek patent protection at its own expense.

 

    	- 39 -

    	 

    
 

 

		15.5	For the avoidance of doubt, the
                                                              gene expression values produced and/or developed by the Testing
                                                              Services (“gene expression values”), as well as all
                                                              designs, developments, ideas, discoveries, inventions and information
                                                              designed, developed, discovered, invented, produced or originated
                                                              by GSK independent of RGI in the course of or as a result of GSK’s
                                                              use or analysis of the gene expression values provided to GSK by
                                                              RGI pursuant to this Master Agreement shall be the sole property
                                                              of GSK . All such designs, developments, ideas, discoveries, inventions
                                                              and information shall be part of the GSK Confidential Information.
                                                              RGI shall reasonably cooperate with GSK in the filing of any necessary
                                                              applications and in otherwise applying for, obtaining or maintaining
                                                              patent, copyright or other protection, and to GSK bearing all necessary
                                                              costs and expenses in relation thereto.

 

		15.6	RGI
                                                                                                hereby grants to GSK a non-exclusive,
                                                                                                fully paid up, irrevocable, worldwide
                                                                                                license
                                                                                                with the right to sublicense
                                                                                                to
                                                                                                intellectual property owned by
                                                                                                RGI solely as is necessary for
                                                                                                GSK to exercise its rights under
                                                                                                this Agreement, including to use
                                                                                                the gene expression values owned
                                                                                                by GSK according to this Master
                                                                                                Agreement.

 

		15.7	RGI shall be entitled to utilize
                                                              the gene expression values (although GSK retains ownership of the
                                                              gene expression values) only for the purposes of this Master Agreement,
                                                              and any designs,
                                                              developments, ideas, discoveries, inventions and information designed,
                                                              developed, discovered, invented, produced or originated by RGI independent
                                                              of GSK in the course of or as a result of RGI’s use of the
                                                              gene expression values provided to GSK by RGI pursuant to this Master
                                                              Agreement shall be the sole and absolute property of GSK. All such
                                                              designs, developments, ideas, discoveries, inventions and information
                                                              shall be part of the Confidential Information of GSK. RGI shall
                                                              reasonably cooperate with GSK in the filing of any necessary applications
                                                              and in otherwise applying for, obtaining or maintaining patent,
                                                              copyright or other protection with regard to any such designs, developments,
                                                              ideas, discoveries, inventions and information, subject to GSK’s
                                                              bearing all necessary costs and expenses in relation thereto.

 

 

    	- 40 -

    	 

    
 

 

		15.8	The Parties shall
                                                              observe all copyrights
                                                              in written material, including computer software, belonging
                                                              to the other Party or any Third Party and will not make any unauthorized
                                                              copies of such material or software.

 

		15.9	Each Party acknowledges that the
                                                              other Party owns certain inventions, processes, know-how, trade
                                                              secrets, improvements and other intellectual property which has
                                                              been independently developed by each Party and which relate to that
                                                              Party’s business or operations. It is acknowledged that the
                                                              intellectual property owned by either Party on the date of this
                                                              Agreement will remain the exclusive property of the owning Party.

 

		15.10	For the avoidance of doubt, RGI
                                                               hereby acknowledges and agrees that the probes and primers for
                                                               the [***] antigens that were subject to or arising from services
                                                               being performed under the Original Agreement shall be solely owned
                                                               by GSK. Without limiting the foregoing and without additional consideration,
                                                               RGI hereby also assigns to GSK all rights, title, and interest
                                                               RGI may have in the probes and primers developed by RGI exclusively
                                                               on behalf of GSK during the term of the Original Agreement, including
                                                               probes and primers for the [***] antigens. RGI agrees to obtain
                                                               written agreements with RGI employees, agents, and subcontractors
                                                               which assign, without additional consideration, all rights, title
                                                               and interests in the probes and primers for the [***] antigens
                                                               that were subject to or arising from services being performed under
                                                               the Original Agreement to GSK or to RGI by which RGI can then assign
                                                               to GSK.

 

 

ARTICLE XVI - REPRESENTATIONS,
WARRANTIES AND COVENANTS

 

		16.1	RGI represents and warrants that
                                                              RGI is not bound by any other agreement under which there would
                                                              be a default or a breach or conflict with as a result of the execution
                                                              and performance of this Master Agreement or a Task Order.

 

		16.2	RGI represents and warrants that
                                                              any computer, hardware, software systems, and any equipment used
                                                              by RGI in connection with Services under a Task Order has been validated
                                                              by RGI for use as required by Applicable Laws or guidelines. RGI
                                                              agrees to provide evidence of such validation as GSK may reasonably
                                                              require.

 

 

    	- 41 -

    	 

    
 

 

		16.3	RGI represents
                                                              and warrants that procedures which are compatible with the EU Data
                                                              Protection Directive (95/46/EC) (the “Directive”)
                                                              or the Applicable Laws or regulations of EU Member States, will
                                                              be employed so that the processing and transfer (as defined in the
                                                              Directive) of personal data, relating to any and all Study data
                                                              subjects, from an EU Member State to a third country which may not
                                                              or does not have data protection legislation at least equivalent
                                                              to that of the EU, will not be impeded by any action initiated on
                                                              the basis of the Directive or corresponding Member State legislation
                                                              or regulations. RGI further represents and warrants that GSK will
                                                              at all times be recognized and, where appropriate (for example,
                                                              informed consents for Study subjects), identified as the Data Controller
                                                              within the meaning of the Directive or the applicable Member State
                                                              legislation. Without limiting the above RGI agrees that it will
                                                              not provide to GSK any names of, or initials of any Study subjects.

 

		16.4	RGI
                                                                                                represents and warrants that RGI
                                                                                                and any employees, agents, and
                                                                                                subcontractors in connection with
                                                                                                this Master Agreement and any
                                                                                                Task Order have not been debarred
                                                                                                under the provisions of the Generic
                                                                                                Drug Enforcement Act of 1992,
                                                                                                21 U.S.C. § 335a (a) and
                                                                                                (b); disqualified as a clinical
                                                                                                testing facility under the provisions
                                                                                                of 21 C.F.R. Part 58, Subpart
                                                                                                K; or disqualified as a clinical
                                                                                                Investigator under the provisions
                                                                                                of 21 C.F.R. § 312.70. RGI
                                                                                                shall notify GSK of any notice
                                                                                                to any of the above of an action
                                                                                                with respect to debarment or disqualification.
                                                                                                The notification obligations of
                                                                                                this Section shall survive termination
                                                                                                of this Master Agreement and any
                                                                                                applicable Task Order.

 

		16.5	RGI represents and warrants that
                                                              RGI will require all employees, agents, and subcontractors in connection
                                                              with this Master Agreement and any Task Order to comply with the
                                                              provisions of this Master Agreement and the applicable Task Order.

 

		16.6	           (a)Upon GSK’s written request, RGI shall in
good faith and without delay, commence and complete the activities outlined in Exhibit H relating to the bridging of the
assays/diagnostic tests used or created as part of the Services to the Third Party(ies) that is(are) developing and will manufacture
and sell the commercial diagnostic test(s) to be used with GSK immunotherapies. Additionally, upon GSK’s written request,
RGI shall in good faith and without delay, commence and complete the activities outlined in Exhibit H relating to the transfer
of the assays/diagnostic tests to a Third Party of GSK’s choosing. GSK shall accept responsibility for the bridging/transfer
activities and RGI makes no representations or warranties, express or implied, that the assays and/or diagnostic tests will not
infringe any Third Party patent or other proprietary rights. Subject to Section 13.6(e) hereof, RGI shall grant to GSK (and such
Affilitates or Third Party(ies) to which GSK may disclose or sublicense intellectual property owned by RGI pursuant to this Master
Agreement, a covenant not-to-sue for its intellectual property (including patents and know-how) that are necessary for GSK (or
its designated Third Party) to practice such assays/diagnostic tests on terms and conditions that are reasonable and customary
in the industry. GSK shall reimburse RGI for its time and out-of-pocket expenses associated with such bridging/transfer activities
pursuant to the fee schedule included in Exhibit H.

 

 

    	- 42 -

    	 

    

 

(b)To
the extent RGI has any contracts or agreements with any Third Parties that are necessary or useful for the ongoing performance
of such assays/diagnostic tests performed as part of the Services associated with the existing Task Orders (including to the extent
applicable, for the avoidance of doubt, the RGI agreement with [***]), then RGI shall use its commercially reasonable efforts
to (upon GSK’s request) provide rights (either via sublicense, assignment or transfer of such agreement as GSK and RGI may
agree) under such contracts or agreements (or the relevant portion thereof) to GSK (or such Third Party, as GSK may request) solely
as part of such bridging/transfer activities. Notwithstanding the foregoing if Third Party consent is required prior to such provision
of rights, then RGI shall use its good faith efforts to obtain such consents. Upon the transfer, assignment or sublicense of such
agreements, GSK agrees to abide by any and all obligations under such transferred, assigned or sublicensed agreements, including
all financial obligations arising out of such agreements which relate to the bridging and transfer obligations, and GSK further
agrees to require its Third Party designees to abide by any and all obligations under such agreements.

 

(c)Notwithstanding
the foregoing, RGI shall not be obligated to undertake any of the aforementioned bridging or transfer activities solely to the
extent it believes in good faith that such activities could breach one or more then-existing Third Party agreements. In such circumstances,
RGI shall consult in good faith with GSK regarding the issues, including providing GSK (under confidence) with true and correct
copies of the applicable Third Party agreement(s) (and any amendments thereto and other relevant materials), if permitted to do
so. If, after consulting with GSK, RGI is unwilling to proceed for materially adverse good faith reasons, then it shall not be
obliged to proceed with such bridging or transfer activities. For the avoidance of doubt, RGI shall perform all aspects of the
aforementioned bridging or transfer activities that are not subject to this Section 16.6(c).

 

 

    	- 43 -

    	 

    
 

 

(d)
If after reviewing the aforementioned Third Party agreements (and any amendments thereto and other relevant materials) GSK
maintains its request to RGI to continue with such bridging or transfer activities and RGI is willing to proceed with such bridging
or transfer activities for materially adverse good faith reasons, then GSK shall pursuant to Article XIX of this Agreement indemnify,
defend, and hold harmless RGI, its officers, agents and employees against any and all Third Party claims, demands, suits, judgments,
expenses and costs, solely arising from or relating to any aspect of the bridging or transfer activities. The indemnification
shall not apply to any activities which RGI conducts outside the scope of the bridging or transfer activities contemplated by
Section 16.6 that are not requested by GSK or its Third Party designee.

 

		16.7	RGI
                                                                                                              shall provide GSK
                                                                                                              with a courtesy
                                                                                                              copy of its quarterly
                                                                                                              reports filed under
                                                                                                              Section 13 of the
                                                                                                              Securities Exchange
                                                                                                              Act of 1934, including
                                                                                                              financial information
                                                                                                              provided in Item
                                                                                                              1, Part I on Form
                                                                                                              10Q. RGI will provide
                                                                                                              this report to GSK
                                                                                                              on the same day
                                                                                                              it files with the
                                                                                                              United States Securities
                                                                                                              and Exchange Commission
                                                                                                              (SEC). In the event
                                                                                                              RGI cease being
                                                                                                              publicly listed,
                                                                                                              then RGI shall on
                                                                                                              a quarterly basis
                                                                                                              provide GSK with
                                                                                                              copies of its then-current
                                                                                                              financial reports
                                                                                                              that substantially
                                                                                                              contain the same
                                                                                                              information that
                                                                                                              was contained in
                                                                                                              the aforementioned
                                                                                                              quarterly reports.
                                                                                                              Should GSK reasonably
                                                                                                              have questions as
                                                                                                              to the content of
                                                                                                              quarterly reports,
                                                                                                              RGI shall reasonably
                                                                                                              comply with such
                                                                                                              requests and promptly
                                                                                                              provide GSK with
                                                                                                              the requested answers.
                                                                                                              

 

 

ARTICLE XVII - ETHICAL STANDARDS
AND HUMAN RIGHTS

 

		17.1	Unless otherwise required or prohibited
                                                              by Applicable Laws, RGI warrants, to the best of its knowledge,
                                                              that in relation to the supply of Services under the terms of the
                                                              Master Agreement and any Task Order:

 

(a)it
does not employ engage or otherwise use any child labor in circumstances such that the tasks performed by any such child labor
could reasonably be foreseen to cause either physical or emotional impairment to the development of such child;

 

 

    	- 44 -

    	 

    
 

 

(b)it
does not use forced labor in any form (prison, indentured, bonded or otherwise) and its employees are not required to lodge papers
or deposits on starting work;

 

(c)it
provides a safe and healthy workplace, presenting no immediate hazards to its employees. Any housing provided by RGI to its employees
is safe for habitation. RGI provides access to clean water, food, and emergency healthcare to its employees in the event of accidents
or incidents at RGI's workplace;

 

(d)it
does not discriminate against any employees on any ground (including race, religion, disability or gender).

 

(e)it
does not engage in or support the use of corporal punishment, mental, physical, sexual or verbal abuse and does not use cruel
or abusive disciplinary practices in the workplace;

 

(f)it
pays each employee at least the minimum wage, or a fair representation of the prevailing industry wage, (whichever is the higher)
and provides each employee with all legally mandated benefits;

 

(g)it
complies with the Applicable Laws on working hours and employment rights in the countries in which it operates; and

 

		(h)	it is respectful of its employees
                                                             right to freedom of association.

 

		17.2	RGI agrees that it is responsible
                                                              for controlling its own supply chain and that it shall reasonably
                                                              encourage compliance with ethical standards and human rights by
                                                              any subsequent supplier of goods and services that are used by RGI
                                                              when performing its obligations under this Master Agreement and
                                                              any Task Order.

 

		17.3	RGI shall ensure that it has ethical
                                                              and human rights policies and an appropriate complaints procedure
                                                              to deal with any breaches of such policies.

 

		17.4	GSK reserves the right upon reasonable
                                                              notice during normal business hours (unless audit is for cause,
                                                              in which case no notice shall be necessary) to enter upon the RGI's
                                                              premises including RGI Facility to monitor compliance by RGI of
                                                              the warranties set out in the Section above and RGI shall, subject
                                                              to compliance with Applicable Laws, furnish GSK with any relevant
                                                              documents reasonably requested by GSK in relation thereto.

 

    	- 45 -

    	 

    
 

 

ARTICLE XVIII - ANTI-BRIBERY AND
CORRUPTION

 

		18.1	RGI acknowledges receipt of the
                                                              ‘Prevention of Corruption – Third Party Guidelines’,
                                                              which are attached as Exhibit F attached to this Master Agreement,
                                                              and agrees to perform its obligations under the Master Agreement
                                                              in accordance with the principles set out therein.

 

		18.2	RGI shall comply fully at all times
                                                              with all Applicable Laws, including but not limited to applicable
                                                              anti-corruption laws, of the territory in which RGI conducts business
                                                              with GSK.

 

		18.3	RGI agrees that it has not, and
                                                              covenants that it will not, in connection with the performance of
                                                              this Master Agreement or any Task Order, promise, authorize, ratify
                                                              or offer to make, or take any act in furtherance of any payment
                                                              or transfer of anything of value, directly or indirectly: (i) to
                                                              any individual including Government Officials (as defined below);
                                                              or (ii) to an intermediary for payment to any individual including
                                                              Government Officials; or (iii) to any political Party. It is the
                                                              intent of the Parties that no payments or transfers of value shall
                                                              be made, promised, authorized, ratified or offered with the purpose
                                                              or effect of public or commercial bribery, acceptance of or acquiescence
                                                              in extortion, kickbacks or other unlawful or improper means of securing
                                                              an improper advantage or obtaining or retaining business.

 

For
the purpose of this Section “Government Official" means: (i) any officer or employee of a government or any
department, agency or instrument of a government; (ii) any person acting in an official capacity for or on behalf of a government
or any department, agency, or instrument of a government; (iii) any officer or employee of a company or business owned in whole
or part by a government; (d) any officer or employee of a public international organization such as the World Bank or United Nations;
(iv) any officer or employee of a political Party or any person acting in an official capacity on behalf of a political Party;
or (v) any candidate for political office.

 

 

    	- 46 -

    	 

    
 

 

		18.4	RGI shall not contact, or otherwise
                                                              meet with any Government Official with respect to any transactions
                                                              required under this Master Agreement or any Task Order, without
                                                              the prior written approval of GSK and, when requested by GSK, only
                                                              in the presence of a GSK designated representative.

 

		18.5	RGI represents that it has not been
                                                              convicted of or pleaded guilty to a criminal offence, including
                                                              one involving fraud, corruption, or moral turpitude, that it is
                                                              not now, to the best of its knowledge, the subject of any government
                                                              investigation for such offenses, and that it is not now listed by
                                                              any government agency as debarred, suspended, proposed for suspension
                                                              or debarment, or otherwise ineligible for government programs.

 

		18.6	RGI represents and warrants that
                                                              except as disclosed in writing: (1) it does not have any interest
                                                              which directly or indirectly conflicts with its proper and ethical
                                                              performance of this Master Agreement and any Task Order(s); and
                                                              (2) it shall maintain arms length relations with all Third Parties
                                                              (including Government Officials) with which it deals in performance
                                                              of this Master Agreement or any Task Order.

 

		18.7	GSK shall have the right during
                                                              the term of this Master Agreement to conduct an investigation and
                                                              audit of RGI to monitor compliance with the terms of this Section
                                                              18. RGI shall reasonably cooperate with such investigation or audit,
                                                              the scope, method, nature and duration of which shall be at the
                                                              sole reasonable discretion of GSK.

 

		18.8	RGI shall ensure that all transactions
                                                              under the Master Agreement and any Task Order are properly and accurately
                                                              recorded in all material respects on its books and records and each
                                                              document upon which entries such books and records are based is
                                                              complete and accurate in all material respects. RGI must maintain
                                                              a system of internal accounting controls reasonably designed to
                                                              ensure that it maintains no off-the-books accounts.

 

		18.9	RGI agrees that GSK may make full
                                                              disclosure of information relating to a possible violation of the
                                                              terms of this Master Agreement at any time and for any reason to
                                                              any competent government bodies and its agencies, and to whomsoever
                                                              GSK determines in good faith has a legitimate need to know.

 

    	- 47 -

    	 

    
 

 

		18.10	GSK
                                                                                                               shall be entitled
                                                                                                               to terminate this
                                                                                                               Master Agreement
                                                                                                               and any Task Order
                                                                                                               immediately on
                                                                                                               written notice
                                                                                                               to RGI, if RGI
                                                                                                               fails to perform
                                                                                                               its obligations
                                                                                                               in accordance with
                                                                                                               this Section 18.
                                                                                                               RGI shall have
                                                                                                               no claim against
                                                                                                               GSK for compensation
                                                                                                               for any loss of
                                                                                                               whatever nature
                                                                                                               by virtue of the
                                                                                                               termination of
                                                                                                               this Master Agreement
                                                                                                               or any Task Orders
                                                                                                               in accordance with
                                                                                                               this Section 18.
                                                                                                               

 

 

ARTICLE XIX - INDEMNIFICATION

 

		19.1	GSK shall indemnify, defend and hold
                                                             RGI and its officers,
                                                             directors, trustees, agents, employees and its Affiliates (individually
                                                             or collectively referred to herein as an “RGI
                                                             Party”) harmless from and against any and
                                                             all losses, liabilities, damages, expenses (but excluding indirect,
                                                             incidental, special, consequential or punitive losses or damages)
                                                             or fees (but only reasonable attorneys fees and expenses and costs
                                                             of litigation pertaining to such RGI
                                                             Claim) paid or payable by RGI
                                                             or a RGI Party
                                                             to a Third Party (collectively, “RGI
                                                             Losses”) to the extent that such RGI
                                                             Losses result from or arise in connection with a claim, suit
                                                             or other proceeding made or brought by a Third Party against RGI
                                                             or a RGI Party
                                                             (a “RGI
                                                             Claim”) based on, resulting from, or arising in connection
                                                             with:

 

(a)the
breach of any material obligation, covenant, agreement, representation or warranty of GSK or a GSK Party contained in this Master
Agreement or any Task Order; or

 

(b)any
material violation of Applicable Laws by GSK, or a GSK Party, in connection with the performance of GSK’s obligations under
this Master Agreement or any Task Order.

 

provided,
however, that GSK shall not be obligated to indemnify, defend or hold harmless RGI
or a RGI Party under this Section from any RGI
Claim or for any RGI Losses to the extent arising out of or attributable
to: (A) a material breach by RGI, or any RGI
Party of any obligation, covenant, agreement, representation or warranty of RGI,
or any RGI Party contained in this Master Agreement or any Task Order, or (B) any
material violation of Applicable Laws by RGI, or a RGI
Party, in connection with the performance of RGI’S obligations under
this Master Agreement or any Task Order, (C) any act or omission by RGI or a RGI
Party, which constitutes recklessness, gross negligence, or willful misconduct on the part of RGI
or a RGI Party, or (D) RGI
Claims to the extent RGI is responsible for indemnifying, defending and holding
GSK and GSK Parties harmless for such claims as set forth in Section 19.2.

 

    	- 48 -

    	 

    
 

 

		19.2	RGI
                                                                                                            shall indemnify,
                                                                                                            defend and hold GSK
                                                                                                            and their respective
                                                                                                            Affiliates, and its
                                                                                                            and their employees,
                                                                                                            agents, officers,
                                                                                                            and directors (individually
                                                                                                            or collectively referred
                                                                                                            to hereinafter as
                                                                                                            a “GSK Party”)
                                                                                                            harmless from and
                                                                                                            against any and all
                                                                                                            losses, liabilities,
                                                                                                            damages, expenses
                                                                                                            (but excluding indirect,
                                                                                                            incidental, special,
                                                                                                            consequential or punitive
                                                                                                            losses or damages)
                                                                                                            or fees (but only
                                                                                                            reasonable attorneys
                                                                                                            fees and expenses
                                                                                                            and costs of litigation
                                                                                                            pertaining to such
                                                                                                            GSK Claim) paid or
                                                                                                            payable by GSK or
                                                                                                            a GSK Party to a Third
                                                                                                            Party (collectively,
                                                                                                            “GSK Losses”)
                                                                                                            to the extent that
                                                                                                            such GSK Losses result
                                                                                                            from or arise in connection
                                                                                                            with a claim, suit
                                                                                                            or other proceeding
                                                                                                            made or brought by
                                                                                                            a Third Party against
                                                                                                            GSK or a GSK Party
                                                                                                            (a “GSK Claim”)
                                                                                                            based on, resulting
                                                                                                            from, or arising in
                                                                                                            connection with:

 

(a)the
breach of any material obligation, covenant, agreement, representation or warranty of RGI
or a RGI Party contained in this Master Agreement or any Task Order; or

 

(b) any
material violation of Applicable Laws by RGI, or a RGI
Party, in connection with the performance of RGI’s obligations under this Master Agreement or any Task Order.

 

provided, however, that RGI
shall not be obligated to indemnify, defend or hold harmless GSK or a GSK Party from any GSK Claim or for any GSK Loss
incurred by GSK or a GSK Party to the extent arising out of, or attributable to, (A) a material breach by GSK or any GSK Party
of any obligation, covenant, agreement, representation or warranty of GSK or a GSK Party contained in this Master Agreement or
any Task Order; or (B) any material violation of Applicable Law by GSK, or a GSK Party, in connection with the performance of
GSK’s obligations under this Master Agreement or any Task Order, (C) any act or omission by GSK, or a GSK Party, which constitutes
recklessness, gross negligence, or willful misconduct on the part of GSK, or a GSK Party, or (D) GSK Claims to the extent GSK
is responsible for indemnifying, defending and holding RGI and RGI
Parties harmless for such claims as set forth in Section 19.1.

 

    	- 49 -

    	 

    
 

 

		19.3	Indemnification Procedures.

 

(a)Each
indemnified Party shall notify (in English) the indemnifying Party in writing (and in reasonable detail) of the Claim within ten
(10) business days after receipt by such indemnified Party of notice of the GSK Claim or RGI
Claim, as the case may be, or otherwise becoming aware of the existence or threatened existence thereof (such GSK Claim
or RGI Claim being referred to as a “Claim”). Failure to give
such notice shall not constitute a defense, in whole or in part, to any claim by an indemnified Party hereunder except to the
extent the rights of the indemnifying Party are materially prejudiced by such failure to give notice. The indemnifying Party shall
notify (in English) the indemnified Party of its intentions as to defense of the Claim or potential Claim in writing within ten
(10) business days after receipt of notice of the Claim. If the indemnifying Party assumes the defense of a Claim against an indemnified
Party, an indemnifying Party shall have no obligation or liability as to any Claim for which settlement or compromise of such
Claim or an offer of settlement or compromise of such Claim is made by an indemnified Party without the prior written consent
of the indemnifying Party, which consent shall not be unreasonably withheld.

 

(b)The
indemnifying Party shall assume exclusive control of the defense and settlement (including all decisions relating to litigation,
defense and appeal) of any such Claim; provided, however, that the indemnifying Party may not settle such Claim in any manner
that would require payment by the indemnified Party, or would materially adversely affect the rights granted to the indemnified
Party hereunder, or would materially conflict with the terms of this Master Agreement, or adversely affect other products, without
first obtaining the indemnified Party’s prior written consent, which consent shall not be unreasonably withheld.

 

(c)The
indemnified Party shall reasonably cooperate with the indemnifying Party in its defense of the Claim at the indemnifying Party’s
expense. If the indemnifying Party assumes defense of the Claim, an indemnified Party may participate in, but not control, the
defense of such Claim using attorneys of its choice and at its sole cost and expense. If an indemnifying Party does not agree
to assume the defense of the Claim asserted against the indemnified Party, or if the indemnifying Party assumes the defense of
the Claim yet fails to defend or take other reasonable, timely action, in response to such Claim asserted against the indemnified
Party, the indemnified Party shall have the right to defend or take other reasonable action to defend its interests in such proceedings,
and shall have the right to litigate, settle or otherwise dispose of any such Claim; provided, however, that no Party shall have
the right to settle a Claim in a manner that would materially conflict with this Master Agreement, or would require a payment
by the Party, or adversely affect the Party (its Affiliates) or its products, without the prior written consent of the Party entitled
to control the defense of such Claim.

 

    	- 50 -

    	 

    
 

 

		19.4	Neither Party nor its Affiliates,
                                                             nor any of its or their respective directors, officers, employees
                                                             or agents shall have any liability for any special, incidental or
                                                             consequential damages, including but not limited to the loss of opportunity,
                                                             loss of use, or loss of revenue or profit in connection with or arising
                                                             out of this Master Agreement or any Task Order even if such Party
                                                             shall have been advised of the possibility of such damages.

 

Article XX – INSURANCE

 

20.1
(a)RGI hereby represents that it has insurance (or is self-insured) for product liability and general liability, and that
it has and will maintain such coverage for the term of this Master Agreement and for a period of two (2) years after the expiration
of this Master Agreement or the earlier termination thereof. Such insurance is in an amount which is reasonable and customary
in the global development and services industry for companies of comparable size and activities. RGI
shall provide a written statement of the existence of such insurance to GSK upon request. 

 

(b)GSK
hereby represents that it is self-insured for product liability and general liability, and that it has and will maintain such
coverage for the term of this Master Agreement and for a period of two (2) years after the expiration of this Master Agreement
or the earlier termination thereof. Such self-insurance is in an amount which is reasonable and customary in the global pharmaceutical
industry for companies of comparable size and activities. GSK shall provide
a written statement of the existence of such insurance to RGI upon request.

 

ARTICLE XXI - DAMAGES

 

    	- 51 -

    	 

    
 

 

		21.1	The Parties agree that a
                                                              failure by RGI to complete Services in a timely manner, as measured
                                                              by any milestone or timeline agreed to in a Task Order, for any
                                                              reason other than GSK’s acts or omissions or an event described
                                                              in Section 23 is a material breach of the relevant Task Order;
                                                              and that such failure would result in damage to GSK but that determining
                                                              the precise extent of that damage would be difficult. Accordingly,
                                                              the Parties agree that, in the event of such a failure by RGI, GSK
                                                              may in addition to any other remedies available to it, deduct from
                                                              payments as reasonable liquidated damages, in light of the anticipated
                                                              or actual loss caused by the breach and the difficulties of proof
                                                              of loss, and not as a penalty, the following amounts, in addition
                                                              to any costs assessed to RGI under Section 2.7(c):

 

(a)[***]
per cent ([***]%) of the value of the appropriate milestone payment for the first full or part of a week that the stated milestone
is delayed beyond the relevant performance date; and

 

(b)[***]
per cent ([***]%) of the value of the appropriate milestone payment for each full or part of a week thereafter that the stated
milestone is further delayed beyond the relevant performance date;

 

(c)up
to a maximum of [***] per cent ([***]%) of the appropriate milestone payment.

 

		21.2	Except as specifically provided
                                                              in this Section, nothing in this Master Agreement or any Task Order
                                                              shall be interpreted as a limitation of liability or waiver by either
                                                              Party of any legal or equitable remedy which may be available to
                                                              that Party.

 

ARTICLE
XXIII - MISCELLANEOUS

 

		23.1	INDEPENDENT
                                                                                                                                   CONTRACTORS.

(a)The
relationship of the Parties is that of independent contractors. Neither Party is the partner, joint venturer, or agent of the
other and neither Party has authority to make any statement, representation, commitment, or action of any kind which purports
to bind the other without the other's prior written authorization.

 

    	- 52 -

    	 

    
 

 

(b)RGI
agrees that no employee or independent contractor of RGI shall be considered an employee of GSK or entitled to any benefits or
eligible for participation in any benefits plans provided to employees of GSK. RGI acknowledges and agrees that RGI is
solely responsible for any wages or compensation payable to employees or independent contractors of RGI, as well as any and all
applicable witholdings of federal, state, or local contributions and taxes in connection with any compensation paid to employees
or independent contractor’s of RGI.

 

		23.2	WAIVER AND RELEASE. Notwithstanding
                                                              anything to the contrary in this Agreement or the Original Agreement,
                                                              RGI (and its Affiliates and shareholders) hereby releases and forever
                                                              hold GSK (and its Affiliates) harmless from any and all claims,
                                                              losses or damages related to or arising out of RGI having opened,
                                                              operated, and subsequently closed that certain laboratory in the
                                                              United Kingdom.

 

		23.3	FORCE MAJEURE.Notwithstanding
anything to the contrary set forth in this Master Agreement, neither Party shall lose any rights hereunder or be liable to the
other Party for damages or losses on account of failure of performance by the defaulting Party, other than a failure to make payment,
if the failure is occasioned by government action, war, terrorism, fire, explosion, flood, strike, lockout, embargo, shortage
of materials or utilities, vendor failure to supply, act of God, or any other cause beyond the control and without the fault or
negligence of the defaulting Party, provided that the Party claiming force majeure has exerted all reasonable efforts to avoid
or remedy such force majeure and that in no event shall a Party be required to settle any labor dispute or disturbance. Such excuse
shall continue as long as the condition preventing the performance continues. Upon cessation of such condition, the affected Party
shall promptly resume performance hereunder. Each Party agrees to give the other Party prompt written notice of the occurrence
of any such condition, the nature thereof, and the extent to which the affected Party will be unable to perform its obligations
hereunder. Each Party further agrees to use all reasonable efforts to correct the force majeure condition as quickly as possible
and to give the other Party prompt written notice when it is again fully able to perform its obligations hereunder; provided if
such event of force majeure continues for a period of in excess of three (3) months, then either Party may terminate this Master
Agreement or any affected Task Order upon providing the other Party prior written notice.

 

    	- 53 -

    	 

    
 

 

		23.4	NOTICES.

 

(a)All
notices under this Master Agreement or a Task Order shall be sent by registered or certified mail, postage prepaid, or by overnight
courier service.  Notices may be sent by facsimile or e-mail, if confirmed by also sending as described above.

 

(b)Notices
pertaining to this Master Agreement shall be sent to:

 

	If to RGI:

        Attn: Chief Executive Officer

        Address:

        1640 Marengo Street,

        Los Angeles, CA 90033

        USA

         

        Copy to:

        RGI Legal Department

        103 S, Carroll Street

        Frederick, MD 21701

         
	If to GSK:

        Attn: VP Diagnostics, Immunotherapeutics

        Address:

        Rue de l’Institut, 89

        1330 Rixensart

        BELGIUM

         

        Copy to:

        GSK Biologicals Legal Department

        Ave Fleming 20

        1300-B Wavre, Belgium

         

Each
party may designate to the other in writing an email address for notice purposes pursuant to this Section 23.4.

 

(c)Notices
pertaining to a Task Order shall be sent to GSK Representatives identified in the Task Order.

 

		23.5	ASSIGNMENT.
                                                                                                                                   GSK
                                                                                                                                   may
                                                                                                                                   assign
                                                                                                                                   its
                                                                                                                                   rights
                                                                                                                                   and
                                                                                                                                   duties
                                                                                                                                   under
                                                                                                                                   this
                                                                                                                                   Master
                                                                                                                                   Agreement
                                                                                                                                   or
                                                                                                                                   any
                                                                                                                                   Task
                                                                                                                                   Order
                                                                                                                                   without
                                                                                                                                   RGI’s
                                                                                                                                   consent;
                                                                                                                                   GSK
                                                                                                                                   shall
                                                                                                                                   notify
                                                                                                                                   RGI
                                                                                                                                   of
                                                                                                                                   any
                                                                                                                                   such
                                                                                                                                   assignment.
                                                                                                                                   Any
                                                                                                                                   assignment
                                                                                                                                   by
                                                                                                                                   RGI
                                                                                                                                   is
                                                                                                                                   valid
                                                                                                                                   only
                                                                                                                                   upon
                                                                                                                                   the
                                                                                                                                   prior
                                                                                                                                   written
                                                                                                                                   consent
                                                                                                                                   of
                                                                                                                                   GSK.
                                                                                                                                   To
                                                                                                                                   the
                                                                                                                                   extent
                                                                                                                                   permitted
                                                                                                                                   above,
                                                                                                                                   this
                                                                                                                                   Master
                                                                                                                                   Agreement
                                                                                                                                   or
                                                                                                                                   any
                                                                                                                                   Task
                                                                                                                                   Order
                                                                                                                                   shall
                                                                                                                                   be
                                                                                                                                   binding
                                                                                                                                   upon
                                                                                                                                   and
                                                                                                                                   inure
                                                                                                                                   to
                                                                                                                                   the
                                                                                                                                   benefit
                                                                                                                                   of
                                                                                                                                   the
                                                                                                                                   Parties
                                                                                                                                   and
                                                                                                                                   their
                                                                                                                                   permitted
                                                                                                                                   successors
                                                                                                                                   and
                                                                                                                                   assigns.

 

		23.6	SEVERABILITY.
                                                                                                                                   If
                                                                                                                                   any
                                                                                                                                   provision(s)
                                                                                                                                   of
                                                                                                                                   this
                                                                                                                                   Master
                                                                                                                                   Agreement
                                                                                                                                   or
                                                                                                                                   a
                                                                                                                                   Task
                                                                                                                                   Order
                                                                                                                                   should
                                                                                                                                   be
                                                                                                                                   illegal
                                                                                                                                   or
                                                                                                                                   unenforceable
                                                                                                                                   in
                                                                                                                                   any
                                                                                                                                   respect,
                                                                                                                                   the
                                                                                                                                   legality
                                                                                                                                   and
                                                                                                                                   enforceability
                                                                                                                                   of
                                                                                                                                   the
                                                                                                                                   remaining
                                                                                                                                   provisions
                                                                                                                                   of
                                                                                                                                   this
                                                                                                                                   Master
                                                                                                                                   Agreement
                                                                                                                                   or
                                                                                                                                   the
                                                                                                                                   Task
                                                                                                                                   Order
                                                                                                                                   shall
                                                                                                                                   not
                                                                                                                                   in
                                                                                                                                   any
                                                                                                                                   way
                                                                                                                                   be
                                                                                                                                   affected.

 

    	- 54 -

    	 

    
 

 

		23.7	WAIVER;
                                                                                                                                   MODIFICATION
                                                                                                                                   OF
                                                                                                                                   AGREEMENT.
                                                                                                                                   No
                                                                                                                                   waiver,
                                                                                                                                   amendment,
                                                                                                                                   or
                                                                                                                                   modification
                                                                                                                                   of
                                                                                                                                   any
                                                                                                                                   of
                                                                                                                                   the
                                                                                                                                   terms
                                                                                                                                   of
                                                                                                                                   this
                                                                                                                                   Master
                                                                                                                                   Agreement
                                                                                                                                   or
                                                                                                                                   a
                                                                                                                                   Task
                                                                                                                                   Order
                                                                                                                                   shall
                                                                                                                                   be
                                                                                                                                   valid
                                                                                                                                   unless
                                                                                                                                   in
                                                                                                                                   writing
                                                                                                                                   and
                                                                                                                                   signed
                                                                                                                                   by
                                                                                                                                   authorized
                                                                                                                                   representatives
                                                                                                                                   of
                                                                                                                                   both
                                                                                                                                   Parties.
                                                                                                                                   Failure
                                                                                                                                   by
                                                                                                                                   either
                                                                                                                                   Party
                                                                                                                                   to
                                                                                                                                   enforce
                                                                                                                                   any
                                                                                                                                   rights
                                                                                                                                   under
                                                                                                                                   this
                                                                                                                                   Master
                                                                                                                                   Agreement
                                                                                                                                   or
                                                                                                                                   a
                                                                                                                                   Task
                                                                                                                                   Order
                                                                                                                                   shall
                                                                                                                                   not
                                                                                                                                   be
                                                                                                                                   construed
                                                                                                                                   as
                                                                                                                                   a
                                                                                                                                   waiver
                                                                                                                                   of
                                                                                                                                   such
                                                                                                                                   rights
                                                                                                                                   nor
                                                                                                                                   shall
                                                                                                                                   a
                                                                                                                                   waiver
                                                                                                                                   by
                                                                                                                                   either
                                                                                                                                   Party
                                                                                                                                   in
                                                                                                                                   one
                                                                                                                                   or
                                                                                                                                   more
                                                                                                                                   instances
                                                                                                                                   be
                                                                                                                                   construed
                                                                                                                                   as
                                                                                                                                   constituting
                                                                                                                                   a
                                                                                                                                   continuing
                                                                                                                                   waiver
                                                                                                                                   or
                                                                                                                                   as
                                                                                                                                   a
                                                                                                                                   waiver
                                                                                                                                   in
                                                                                                                                   other
                                                                                                                                   instances.

 

		23.8	GOVERNING LAW;
                                                                                VENUE. This Master Agreement will be
                                                                                governed by and construed in accordance with the
                                                                                laws of Belgium, without regard to its conflict
                                                                                of laws or choice of laws principles. The Parties
                                                                                agree that any disputes arising under this agreement
                                                                                shall be presented exclusively before the courts
                                                                                of the State of Delaware
                                                                                in the United States in cases RGI is the respondent,
                                                                                and in Nivelles, Belgium, in cases GSK is the
                                                                                respondent. Each Party hereby submits itself to
                                                                                the personal jurisdiction and venue of such courts
                                                                                in connection with any such proceedings, and agrees
                                                                                to accept service of process by mail.

 

		23.9	COUNTERPARTS.
                                                                                                                                   This
                                                                                                                                   Master
                                                                                                                                   Agreement
                                                                                                                                   and
                                                                                                                                   any
                                                                                                                                   Task
                                                                                                                                   Order
                                                                                                                                   may
                                                                                                                                   be
                                                                                                                                   executed
                                                                                                                                   in
                                                                                                                                   one
                                                                                                                                   or
                                                                                                                                   more
                                                                                                                                   counterparts
                                                                                                                                   including
                                                                                                                                   facsimile
                                                                                                                                   or
                                                                                                                                   PDF
                                                                                                                                   copies
                                                                                                                                   transmitted
                                                                                                                                   electronically,each
                                                                                                                                   of
                                                                                                                                   which
                                                                                                                                   shall
                                                                                                                                   be
                                                                                                                                   deemed
                                                                                                                                   an
                                                                                                                                   original
                                                                                                                                   and
                                                                                                                                   all
                                                                                                                                   of
                                                                                                                                   which
                                                                                                                                   shall
                                                                                                                                   constitute
                                                                                                                                   the
                                                                                                                                   same
                                                                                                                                   instrument.

 

		23.10	ENTIRE AGREEMENT.
This Master Agreement, in conjunction with individual Task Orders entered into under this Master Agreement,
as well as all schedules and exhibits to this Master Agreement and any Task Orders constitute the entire agreement and understanding
between the Parties with respect to the subject matter hereof and supersedes any prior agreement, understanding or arrangement
between the Parties, whether oral or in writing as of the Effective Date. No representation, undertaking or promise shall be taken
to have been given or be implied from anything said or written in negotiations between the Parties prior to this Master Agreement
except as expressly stated in this Master Agreement.

 

    	- 55 -

    	 

    
 

 

		23.11	FURTHER ASSURANCES.
The Parties shall do and execute all such further acts and things as are reasonably required to give full effect to the
rights given and the transactions contemplated by this Master Agreement.

 

		23.12	INTERNATIONAL
                                                               SALE OF GOODS ACT. The Parties acknowledge and
                                                               agree that the International Sale of Goods Act and the United Nations
                                                               Convention on Contracts for the International Sale of Goods have
                                                               no application to this Agreement.

 

		23.13	COSTS. Except as is
otherwise expressly set forth herein, each Party shall bear its own expenses in connection with the negotiation of this Agreement.

 

 

SIGNATURE PAGE TO FOLLOW

 

    	- 56 -

    	 

    
 

 

IN WITNESS whereof the hands
of the Parties or their duly authorised representatives on the date first above written.

 

 

	GLAXOSMITHKLINE BIOLOGICALS SA	RESPONSE GENETICS INC.
	 	 
	 	 
	 	 
	By: /s/ Jamila Louahed	By: /s/ Thomas A. Bologna
	 	 
	Name: Jamila Louahed	Name: Thomas A. Bologna
	 	 
	Title: VP Research & Development,	Title: CEO
	Immunotherapeutics	 
	 	Date: July 26, 2012
	Date: July 26, 2012	 
	 	 
	By: /s/ Emmanuel Hannon	 
	 	 
	Name: Emmanuel Hannon	 
	 	 
	Title: Senior VP, Head of Vaccines Discovery	 
	and Development	 
	 	 
	Date: July 26, 2012	 
	 	 
	By: /s/ Sophie Lelong	 
	 	 
	Name: Sophie Lelong	 
	 	 
	Title: Senior Manager Procurement	 
	 	 
	Date: July 26, 2012	 

 

    	- 57 -

    	 

    
 

EXHIBIT A - FORM
TASK ORDER AND SCHEDULES

	PO number 

        to be inserted on each invoice

 

TASK ORDER RGI-XXX

 

This
TASK ORDER is effective as of the ....... Day of ............. (the “Effective Date”)
between RESPONSE GENETICS INC., a company incorporated in the State of Delaware, whose
principal place of business is situated at 1640 Marengo Street, Suite 600, Los Angeles, CA 90033 and
GLAXOSMITHKLINE BIOLOGICALS SA, with offices located at 89 rue de l’Institut, 1330 Rixensart, BELGIUM (“GSK”).

 

BACKGROUND

 

GSK and RGI are Parties to a second Amended
and Restated Master Agreement (hereinafter referred to as the “Master Agreement”) with an effective date of <INSERT
DATE>.

 

 

	TASK ORDER EFFECTIVE DATE:	<INSERT DATE>
	GSK PROJECT NAME :	<INSERT PROJECT NAME>
	STUDY TITLE:	<INSERT STUDY TITLE>
	ASSAY NAME:	<INSERT ASSAY NAME>
	RGI Monitor:	<INSERT NAME>
	GSK  Representative:	<INSERT NAME lab coordinator>
	TASK ORDER EXPIRATION DATE:	<INSERT DATE>

 

 

		1.	THE SERVICES

 

RGI agrees to perform the
Services as outlined in Schedule A and if appropriate, in Schedule C, attached and incorporated by reference as part of this Task
Order, and in accordance with the terms of the Master Agreement.

 

		2.	COMPENSATION

 

In consideration for its performance
of Services under this Task Order, GSK shall pay RGI in accordance with the payment schedule as documented in Schedule B, attached
and incorporated by reference as part of this Task Order.

 

    	- 58 -

    	 

    
 

 

		3.	SAMPLE STORAGE

 

			The Samples provided by GSK to RGI are
                                                          listed in Schedule E of this Task Order and are to be stored in accordance
                                                          to section 4.1 and 6 of the Master Agreement.

 

		3.	TERM; TERMINATION

 

This Task Order shall continue
until the Services are completed in accordance with the timelines set forth in Schedule A attached to this Task Order or until
terminated as provided in the Master Agreement.

 

		4.	INCORPORATION OF MASTER AGREEMENT BY REFERENCE

 

The Terms and Conditions of
the Master Agreement are hereby incorporated by reference into and made a part of this Task Order. Unless otherwise stated in
this Task Order, all defined terms within the Master Agreement shall have the same meaning when used in this Task Order. If any
provisions of this Task Order are in direct conflict with the Master Agreement so that the provisions of both cannot be given
effect, the terms of this Task Order shall govern the specific issue.

 

		5.	NOTICE.

 

In addition to the recipients
of notice listed in the Master Agreement, notices applicable to this Task Order Agreement shall be sent to:

 

		6.	APPLICABLE STANDARDS.

 

 

    	- 59 -

    	 

    

[INSERT ANY APPLICABLE
STANDARDS TO WHICH THE WORK SHOULD BE PERFORMED, CLIA, EU Directives, ETC]

 

	RGI Monitor:

        Name: <INSERT NAME>

         

        Address :

        <INSERT ADDRESS>

         

         

        Email address: <INSERT E-MAIL
        ADDRESS>

        Copy to:
	GSK representative:

        Name: <INSERT NAME lab coordinator>

        Address :

        Rue de l’Institut, 89

        1330 Rixensart

        BELGIUM

        Email address: <INSERT E-MAIL
        ADDRESS>

        Copy to: <INSERT NAME contract
        manager>

 

 

		7.	ENTIRE AGREEMENT.

 

This Task Order, including the
incorporated Terms and Conditions of the Master Agreement, represent the entire and integrated agreement between RGI and GSK and
supersedes all prior negotiations, representations or agreements, either written or oral, regarding the Services subject of this
Task Order.

 

 

	GLAXOSMITHKLINE BIOLOGICALS SA

         

        By: ____________________________

         

        Name:

         

        Title:

         

        Date: _________________
	RESPONSE GENETICS INC.

         

        By: ___________________________

         

        Name:

         

        Title:

         

        Date: _________________

 

    	- 60 -

    	 

    

 

SCHEDULE A – DESCRIPTION OF SERVICES

 

		-	Reference to Study Protocol (if applicable)

		-	Analytical Plan or similar

		o	Study

		o	Serology or assay

		o	Goal of Services

		o	Milestone schedule with timing

		o	Deliverables

		o	Reporting schedule (regular reporting, milestone
reports,..)

		-	Key contact persons at GSK and RGI side

		-	KPI specific on activity

 

 

    	- 61 -

    	 

    
 

 

SCHEDULE B – BUDGET RELATING TO THE SERVICES

 

Payment schedule should be generally cost
neutral throughout performance period, i.e. payments will be made according to the Services actually achieved during the invoiced
period.

 

Invoices should be dispatched regularly
at least every two (2) months throughout the course of the Master Agreement.

The invoices should mention the purchase
order (PO) to be provided by GSK (usually noted on the first page of the original Task Order document).

All payments will be made within sixty
(60) days from the end of month from the date of receipt of the invoice.

 

Total budget 

		-	Including cost of all requested Services

		-	on basis of the (estimated) number of Samples to
be tested and price per (final) result

 

 

    	- 62 -

    	 

    
 

 

SCHEDULE C – PROCEDURES AND PROTOCOLS

 

Procedures

In light
of the Services described in Schedule A, a controlled copy of all Procedures and policies mentioned below was sent to RGI at the
indicated dates.

 

RGI is required to follow the Procedures
from GSK, listed below.

If Procedures from RGI are used, a copy
shall be provided to GSK and the reference and title of these Procedures are mentioned below. Any changes to a Procedure used
for the Services need to be agreed and approved by both Parties in written before implementation of such change.

  

Procedures GSK : 

		-	1

		-	2

 

Procedures RGI :

		-	1

		-	2

 

    	- 63 -

    	 

    
 

 

SCHEDULE D – PRICING TERMS

 

DISCOUNT
/ REBATE / PRICING TERMS SPECIFICALLY AGREED TO FOR THIS TASK ORDER (IF APPLICABLE)

 

Breakdown of unit prices

		-	Agreed price proposal

		-	milestone price for assay development

		-	price per final result for routine

 

    	- 64 -

    	 

    
 

 

SCHEDULE
E – SAMPLES, MATERIALS & GSK EQUIPMENT

 

Samples: 

Description of Samples that will be provided
to RGI by GSK or its Affiliate during the term of this Master Agreement to perform the Services hereunder, indicating a scale
of value.

 

		-	1

		-	2

		 	-

 

Materials : 

List of active and raw materials, reagents,
intermediates, processing aids, ingredients or components, documentation and other materials that will be provided to RGI by GSK
or its Affiliate during the term of this Master Agreement to perform the Services hereunder :

 

		-	1

		-	2

		 	-

 

All
Materials to be provided by GSK will be shipped to the following shipping address:

<INSERT SHIPPING ADDRESS RGI>

 

GSK Equipment : 

List
of equipment that will be provided to RGI by GSK or its Affiliate during the term of this Task Order to perform the Services described
in Schedule A : 

if
applicable

 

    	- 65 -

    	 

    
 

 

 

EXHIBIT
B – CHANGE ORDER FORM

 

CHANGE ORDER 

 

		1.	All Change Orders shall be identified by

 

	Change Order number:	____________
	date submitted:	____________
	application date:	____________
	Task Order(s) to amend:	____________

 

		2.	Describe and motivate changes, modifications, or additions
to the Services.

  

 

		3.	These modifications were requested by

	[_]	GSK
	[_]	RGI

 

		4.	Impact on

		-	Cost: (if applicable)

		o	initial cost of Study :

		o	changes in cost :

		o	new final cost of Study :

		-	Timing / Schedule: (if applicable)

		o	Task Order will remain effective
                                                               until __________

		-	any other requirement: (if applicable)

 

 

 

    	- 66 -

    	 

    

 

SIGNATURE PAGE TO FOLLOW

		5.	Change Order Is:

 

	Approved and Accepted________	 	 
	 	 	 
	 	 	 
	______________________ __________	__________ _____	 
	Signature of GSK	Date	 
	Name :	 	 
	Title :	 	 
	 	 	 
	______________________ __________	__________ _____	 
	Signature of RGI	Date	 
	Name : 		 
	Title :	 	 
	 	 	 

 

    	- 67 -

    	 

    

 

EXHIBIT
C – KEY PERFORMANCE INDICATORS

[***]

[***]

[***]

[***]

 

KPI
specific on activity will be specified in TO

 

 

    	- 68 -

    	 

    
 

EXHIBIT D – RATE CARD / PRICE SCHEDULE/DISCOUNT

 

	 	Service	Explanation of service	Fee per sample
 Expedited Reporting	Fee per sample

    Non-expedited Reporting

    (can be Batched)
	Extraction by “tumor cells” technique
	

1	[***]	[***]	[***]	[***]
	

2	[***]	[***]	[***]	[***]
	

3	[***]	[***]	[***]	[***]
	Extraction by “tumor area” technique
	

4	[***]	[***]	[***]	[***]
	

5	[***]	[***]	[***]	[***]
	

6	[***]	[***]	[***]	[***]
	Analysis activities
	

7	[***]	[***]	[***]	[***]
	

8	[***]	[***]	[***]	[***]
	

9	[***]	[***]	[***]	[***]
	

10	[***]	[***]	[***]	[***]
	

11	[***]	[***]	[***]	[***]
	

12	[***]	[***]	[***]	[***]

 

 

    	- 69 -

    	 

    

 

 

	 	Service	Explanation of service	Fee per sample
 Expedited Reporting	Fee per sample

    Non-expedited Reporting

    (can be Batched)
	

13	[***]	[***]	[***]	[***]
	

14	[***]	[***]	[***]	[***]
	

15	[***]	[***]	[***]	[***]
	

16	[***]	[***]	[***]	[***]
	

17	[***]	[***]	[***]	[***]
	

18	[***]	[***]	[***]	[***]
	

19	[***]	[***]	[***]	[***]
	Other Activities
	

20	[***]	[***]	[***]	[***]
	

21	[***]	[***]	[***]	[***]

  

 

[***]

 

 

 

    	- 70 -

    	 

    

 

EXHIBIT F - PREVENTION OF CORRUPTION – THIRD PARTY GUIDELINES

 

The GSK Anti-Bribery and Corruption Policy
(POL-GSK-007) requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries
in which GSK (whether through a Third Party or otherwise) conducts business. POL-GSK-007 requires all GSK employees and any Third
Party acting for or on behalf of GSK to ensure that all dealings with Third Parties, both in the private and government sectors,
are carried out in compliance with all relevant laws and regulations and with the standards of integrity required for all GSK
business. GSK values integrity and transparency and has zero tolerance for corrupt activities of any kind, whether committed by
GSK employees, officers, or Third Parties acting for or on behalf of the GSK.

 

Corrupt Payments – GSK employees
and any Third Party acting for or on behalf of GSK, shall not, directly or indirectly, promise, authorise, ratify or offer to
make or make any “payments” of “anything of value” (as defined in the glossary section) to any individual
(or at the request of any individual) including a “government official” (as defined in the glossary section) for the
improper purpose of influencing or inducing or as a reward for any act, omission or decision to secure an improper advantage or
to improperly assist the company in obtaining or retaining business.

 

Government Officials – Although
GSK ́s policy prohibits payments by GSK or Third Parties acting for or on its behalf to any individual, private or public,
as a “quid pro quo” for business, due to the existence of specific anticorruption laws in the countries where we operate,
this policy is particularly applicable to “payments” of “anything of value” (as defined in the glossary
section), or at the request of, “government officials” (as defined in the glossary section).

 

Facilitating Payments – For
the avoidance of doubt, facilitating payments (otherwise known as “greasing payments” and defined as payments to an
individual to secure or expedite the performance of a routine government action by government officials) are no exception to the
general rule and therefore prohibited.

 

GLOSSARY

 

The terms defined herein should be construed
broadly to give effect to the letter and spirit of the ABAC Policy. GSK is committed to the highest ethical standards of business
dealings and any acts that create the appearance of promising, offering, giving or authorising payments prohibited by this policy
will not be tolerated.

 

Anything of Value: this term includes
cash or cash equivalents, gifts, services, employment offers, loans, travel expenses, entertainment, political contributions,
charitable donations, subsidies, per diem payments, sponsorships, honoraria or provision of any other asset, even if nominal in
value.

 

    	- 71 -

    	 

    
 

 

Payments: this term refers to and
includes any direct or indirect offers to pay, promises to pay, authorisations of or payments of anything of value.

Government Official shall mean:

 

		·	Any
officer or employee of a government or any department, agency or instrument of a government;

 

		·	Any
person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government;

 

		·	Any
officer or employee of a company or business owned in whole or part by a government;

 

		·	Any
officer or employee of a public international organisation such as the World Bank or United Nations;

 

		·	Any
officer or employee of a political Party or any person acting in an official capacity on behalf of a political Party; or

 

		·	Any
candidate for political office.

 

 

    	- 72 -

    	 

    
 

 

EXHIBIT
G – LABORATORY QUALITY ASSESSMENT ACTION PLAN

 

 

NA

 

    	- 73 -

    	 

    
 

 

EXHIBIT H – TECHNOLOGY TRANSFER
PROVISIONS

 

 

[***]

[***]

		•	[***]

		•	[***]

		•	[***]

		•	[***]

		•	[***]

[***]

		•	[***]

		•	[***]

		•	[***]

		•	[***]

[***]

		•	[***]

		•	[***]

		•	[***]

		•	[***]

[***]

		•	[***]

		•	[***]

		•	[***]

		•	[***]

[***]

		·	[***]

 

    	- 74 -

    	 

    
 

 

EXHIBIT I – STATEMENTS OF WORK

 

	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 
	[***]	[***]	 
	 	[***]	 
	 	[***]	 

 

    	- 75 -Exhibit 4.7

 

MEDGENICS,
INC.

 

Non-Qualified
Stock Option Award Terms

 

Pursuant to the employment
inducement grant exception to the shareholder approval requirements contained in Section 711 of the NYSE MKT Rules, the Participant
specified below has been granted an Option by Medgenics, Inc., a Delaware
corporation (the “Company”), it being understood that such grant has not been made pursuant to the Medgenics,
Inc. Stock Incentive Plan, as amended from time to time (the “Incentive
Plan”) or any other equity-based incentive plan of the Company or its Affiliates; provided that, other than as
is inconsistent with the Option Terms, the Option Terms shall be administered consistent with the provisions of the Incentive Plan,
the terms of which are incorporated herein by reference. The Option shall be subject to the following terms and conditions (the
“Option Terms”):

 

Section
1.          Terms of Award. The following words and phrases
relating to the grant of the Option shall have the following meanings:

 

(a)        The
“Participant” is Sol J. Barer.

 

(b)        The
“Date of Grant” is June 30, 2012.

 

(c)        The
number of “Covered Shares” is 900,000 shares of Common Stock.

 

(d)        The
“Exercise Price” is $10.80 per share of Common Stock.

 

(e)        The
“Effective Date” is the date the additional listing application for the issuance of the Covered Shares is approved
by the NYSE MKT has been approved by the NYSE MKT.

 

Except where the context
clearly implies to the contrary, any capitalized term in the Option Terms shall have the meaning ascribed to that term under the
Incentive Plan.

 

Section
2.          Non-Qualified Stock Option. The Option is not
intended to constitute an “incentive stock option” as that term is used in Code Section 422.

 

Section
3.          Date of Exercise. Each installment of Covered
Shares of the Option (“Installment”) shall become vested and exercisable on and after the “Vesting
Date” for such Installment as described in the following schedule (but only if the Participant’s Termination of
Service has not occurred before the Vesting Date):

 

	 	 	VESTING DATE
	INSTALLMENT	 	APPLICABLE TO INSTALLMENT
	300,000 Covered Shares	 	Effective Date
	300,000 Covered Shares	 	June 30, 2013
	300,000 Covered Shares	 	June 30, 2014

 

    	 

    	 

    

 

(a)        Notwithstanding
the foregoing provisions of this Section 3, the Option shall become fully exercisable upon a Change in Control that occurs
on or before the Participant’s Termination of Service.

 

(b)        The
Option may be exercised on or after the Participant’s Termination of Service only as to that portion of the Covered Shares
for which it was exercisable immediately prior to the Participant’s Termination of Service, or became exercisable on the
date of the Participant’s Termination of Service.

 

Section
4.          Expiration. The Option shall not be exercisable
after the Company’s close of business on the last business day that occurs prior to the Expiration Date. The “Expiration
Date” shall be the earliest to occur of:

 

(a)        June
30, 2017; or

 

(b)        the
12-month anniversary of the Participant’s Termination of Service if such termination occurs due to death or Disability; or

 

(c)        the
90th day following the Participant’s Termination of Service if such termination occurs for any reason other than
death, Disability or Cause; or

 

(d)        the
effective date of a Termination of Service where such Termination of Service is for Cause.

 

For purposes
of this Agreement, “Cause” shall have the meaning set forth in the employment or similar agreement entered into
by and between the Participant and the Company, if any. In the absence of any such agreement, “Cause” shall mean (1)
any act by the Participant of (A) fraud or intentional misrepresentation, or (B) embezzlement, misappropriation or conversion of
assets or opportunities of the Company or any Affiliate, or (2) any willful violation of any law, rule or regulation in connection
with the performance of the Participant’s duties (other than traffic violations or similar offenses), or (3) with respect
to any employee of the Company or any Affiliate, commission of any act of moral turpitude or conviction of a felony, or (4) the
willful or negligent failure of the Participant to perform his duties in any material respect.

 

Section
5.          Method of Option Exercise. Subject to the Option
Terms, the Option may be exercised in whole or in part by filing a written notice with the Secretary of the Company at its corporate
headquarters prior to the Company’s close of business on the last business day that occurs prior to the Expiration Date,
together with a signed Investment Representation Statement in a form substantially similar to the form attached hereto as Exhibit A
in the event that the Common Stock to be issued to the holder will not be registered under the Securities Act of 1933, as amended.
Such notice shall specify the number of shares of Common Stock which the Participant elects to purchase, and shall be accompanied
by payment of the Exercise Price for such shares of Common Stock indicated by the Participant’s election. Payment of the
Exercise Price shall be in cash or by wire transfer of immediately available funds. The Option shall not be exercisable if and
to the extent the Company determines that such exercise would violate applicable state or federal securities laws or the rules
and regulations of any securities exchange on which the Common Stock is traded and shall not be exercisable during any blackout
period established by the Company from time to time.

 

    	2

    	 

    

 

Section
6.          Withholding. The exercise of the Option is subject
to withholding of all applicable taxes. At the election of the Participant, and subject to such rules and limitations as may be
established by the Committee from time to time, such withholding obligations shall be satisfied through cash payment or wire transfer
of immediately available funds by the Participant.

 

Section
7.          Transferability. Without the prior approval
of the Company, the Option is not transferable by the Participant other than by will or by the laws of descent and distribution,
and during the Participant’s life, may be exercised only by the Participant. Without the prior approval of the Company, the
Option may not be assigned, transferred (except as aforesaid), pledged or hypothecated by the Participant in any way whether by
operation of law or otherwise, and shall not be subject to execution, attachment or similar process. Any attempt at assignment,
transfer, pledge or hypothecation, or other disposition of the Option contrary to the provisions hereof, and the levy of any attachment
or similar process upon the Option, shall be null and void and without effect.

 

Section
8.          Heirs and Successors. The Option Terms shall
be binding upon, and inure to the benefit of, the Company and its successors and assigns, and upon any person acquiring, whether
by merger, consolidation, purchase of assets or otherwise, all or substantially all of the Company’s assets and business.
If any rights of the Participant or benefits distributable to the Participant under the Option Terms have not been exercised or
distributed, respectively, at the time of the Participant’s death, such rights shall be exercisable by the Designated Beneficiary,
and such benefits shall be distributed to the Designated Beneficiary, in accordance with the provisions of the Option Terms and
the Incentive Plan. The “Designated Beneficiary” shall be the beneficiary or beneficiaries designated by the
Participant in a writing filed with the Committee in such form and at such time as the Committee shall require. If a Participant
fails to designate a beneficiary, or if the Designated Beneficiary does not survive the Participant, any rights that would have
been exercisable by the Participant and any benefits distributable to the Participant shall be exercised by or distributed to the
legal representative of the estate of the Participant. If a Participant designates a beneficiary and the Designated Beneficiary
survives the Participant but dies before the Designated Beneficiary’s exercise of all rights under the Option Terms or before
the complete distribution of benefits to the Designated Beneficiary under the Option Terms, then any rights that would have been
exercisable by the Designated Beneficiary shall be exercised by the legal representative of the estate of the Designated Beneficiary,
and any benefits distributable to the Designated Beneficiary shall be distributed to the legal representative of the estate of
the Designated Beneficiary.

 

Section
9.          Administration. The authority to manage and
control the operation and administration of the Option Terms and the Incentive Plan shall be vested in the Committee, and the Committee
shall have all powers with respect to the Option Terms as it has with respect to the Incentive Plan. Any interpretation of the
Option Terms or the Incentive Plan by the Committee and any decision made by it with respect to the Option Terms or the Incentive
Plan are final and binding on all persons.

 

    	3

    	 

    

 

Section
10.         Incentive Plan Governs. Notwithstanding anything
in the Option Terms to the contrary, the Option Terms shall be subject to the terms of the Incentive Plan, a copy of which may
be obtained by the Participant from the Secretary of the Company, in a manner consistent as if the Option were granted pursuant
to the Incentive Plan; and the Option Terms shall be subject to all interpretations, amendments, rules and regulations promulgated
by the Committee from time to time pursuant to and applicable to awards granted under the Incentive Plan; provided, however,
that payment of the Exercise Price under the Option shall in all events be in cash or by wire transfer of immediately available
funds. Notwithstanding anything in the Option Terms to the contrary, in the event of any discrepancy between the corporate records
of the Company and the Option Terms, the corporate records of the Company shall control.

 

Section
11.         Not An Employment Contract. The Option shall not
confer on the Participant any right with respect to continuance of employment or other service with the Company or any Affiliate,
nor shall it interfere in any way with any right the Company or any Affiliate would otherwise have to terminate or modify the terms
of such Participant’s employment or other service at any time.

 

Section
12.         No Rights As Shareholder. The Participant shall not
have any rights of a shareholder with respect to the Covered Shares subject to the Option until the Participant becomes the holder
of record of such Covered Shares.

 

Section
13.         Amendment. The Option Terms may be amended in accordance
with the provisions of the Incentive Plan as applicable to awards granted under the Incentive Plan, and may otherwise be amended
by written agreement of the Participant and the Company without the consent of any other person.

 

Section 14.         Validity.
If any provision of the Option Terms is determined to be illegal or invalid for any reason, said illegality or invalidity shall
not affect the remaining parts hereof, but the Option Terms shall be construed and enforced as if such illegal or invalid provision
had never been included herein.

 

Section 15         Section
409A Amendment. The Committee reserves the right (including the right to delegate such right) to unilaterally amend the
Option Terms without the consent of the Participant to maintain compliance with Code Section 409A. The Participant’s acceptance
of the Option constitutes acknowledgement and consent to such rights of the Committee.

 

Section 16.         Clawback.
The Option shall be subject to potential cancellation, recoupment, rescission, payback or other similar action in accordance
with the terms of any applicable Company clawback policy (the “Policy”) or any applicable law. The Participant’s
acceptance of the Option constitutes acknowledgement and consent to the Company’s application, implementation and enforcement
of (a) the Policy and any similar policy established by the Company that may apply to the Participant and (b) any provision of
applicable law relating to cancellation, rescission, payback or recoupment of compensation, as well as the Participant’s
express agreement that the Company may take such actions as are necessary to effectuate the Policy, any similar policy and applicable
law, without further consideration or action.

 

    	4

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused the Option Terms to be executed on its behalf by a duly authorized officer and Participant has executed
the Option Terms.

 

	PARTICIPANT	 	MEDGENICS, INC.

 

	       /s/ Sol J. Barer	 	By:	/s/ Phyllis K. Bellin
	Signature	 	 	 
	 	 	 	 
	  Sol J. Barer	 	 	Its:  Vice President – Administration
	Print Name	 	 	 

 

    	 

    	 

    

 

Exhibit
A

 

INVESTMENT REPRESENTATION STATEMENT

 

[This form is to be completed at the
time the Option is exercised, unless the stock to be issued 

upon exercise of the Option has been registered under the Securities
Act of 1933, as amended]

 

Effective as of ___________________
[insert date of option exercise] (the “Effective Date”), the undersigned (“Participant”) has elected
to purchase ___________________ shares of the Common Stock (the “Shares”) of Medgenics, Inc. (the “Company”)
under and pursuant to the Non-Qualified Stock Option Terms dated ___________________ [insert grant date of option] (the
“Option Terms”). The Participant hereby makes the following certifications, representations, warranties and agreements
with respect to the purchase of the Shares:

 

The Participant acknowledges
that he or she is aware of the Company’s business affairs and financial condition and has acquired sufficient information
about the Company to reach an informed and knowledgeable decision to acquire the Shares. The Participant represents and warrants
to the Company that he or she is acquiring these Shares for investment for the Participant’s own account only and not with
a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act of
1933, as amended (the “Securities Act”).

 

The Participant further
acknowledges that the Shares have not been registered under the Securities Act, are deemed to constitute “restricted securities”
under Rule 701 and Rule 144 promulgated under the Securities Act and must be held indefinitely unless they are subsequently registered
under the Securities Act and qualified under any applicable state securities laws or an exemption from such registration and qualification
is available. The Participant further acknowledges that the Company is under no obligation to register the Shares.

 

The Participant further
acknowledges that he or she is familiar with the provisions of Rule 144, which, in substance, permits limited public resale of
“restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject
to the satisfaction of certain conditions. The Participant further acknowledges that in the event all of the applicable requirements
of Rule 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration
exemption will be required in order to resell the Shares. The Participant understands that no assurances can be given that any
such registration will be made or any such exemption will be available in such event.

 

The Participant further
acknowledges and understands that all certificates representing any of the Shares shall have endorsed thereon appropriate legends
reflecting the foregoing limitations, as well as any legends reflecting any other restrictions pursuant to the Company’s
Articles of Incorporation, Bylaws, the Option Terms, the Medgenics, Inc. Stock Incentive Plan and/or applicable securities laws.

 

    	A-1

    	 

    

 

The Participant further
agrees that, if so requested by the Company or any representative of the underwriters (the “Managing Underwriter”)
in connection with any registration of the offering of any securities of the Company under the Securities Act, the Participant
shall not sell or otherwise transfer any Shares or other securities of the Company during the 180-day period, or such other period
as may be requested in writing by the Managing Underwriter and agreed to in writing by the Company (the “Market Standoff
Period”), following the effective date of a registration statement of the Company filed under the Securities Act. Such restriction
shall apply only to the first registration statement of the Company to become effective under the Securities Act that includes
securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act. The Company
may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market
Standoff Period.

 

The Participant further
acknowledges and agrees that the Company shall not be required (i) to transfer on its books any Shares that have been sold
or otherwise transferred in violation of any of the representations, warranties, agreements or other provisions contained in this
Investment Representation Statement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to
any purchaser or other transferee to whom such Shares shall have been so transferred.

 

	 	Submitted by Participant:
	 	 
	 	 
	 	Signature

 

    	A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]